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SYNOPSIS
1A comprehensive summary of the work incorporated in the thesis with the title
“STUDIES ON CHEMICAL ENTITIES OF THERAPEUTIC INTEREST” has been
described as under.
[A] STUDIES ON IMIDAZO[1,2,-a]PYRIDINES
[B] STUDSIES ON DIFLUOROBENZENE DERIVATIVES
[A] STUDIES ON IMIDAZO[1,2,-a]PYRIDINES
The aim of the research work is to develop a new bioactive entities, especially
with pharmacological activities bearing heterocyclic ring system namely imidazo[1,2-
a]pyridine. Our efforts are focused on introduction of chemical diversity in the
molecular frame work in order to synthesizing therapeutically active molecule of widely
different composition.
Heterocyclic compounds bearing imidazo[1,2-a]pyridine ring system are endowed
with a variety of biological activities such as antimicrobial, anticonvulsant, hypnotic,
anti-inflammatory, antitubercular, antitumor, anticancer, herbicidal and many other
therapeutic activities.
Keeping in association with the various biological activities and industrial
applications of  imidazo[1,2-a]pyridines, it was thought worthwhile to synthesize some
new heterocycles which have been described as under.
PART-I : STUDIES ON PYRAZOLINES
Substituted pyrazoline derivatives have drawn considerable attention of the chemist
due to their good pharmacological activities like antibacterial, anticonvulsant, analgesic etc.
With a view to getting better therapeutic agent and to evaluate pharmacological
profile, different type of pyrazoline derivatives have been prepared which have been
described as under.
2SECTION-I : Synthesis and biological evaluation of (2E)-3-[2-(4-Chlorophenyl)
 imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones
The chalcone derivatives of Type (I) have been synthesized by the condensation
of 2-(4-chlorophenayl)imidazo[1,2-a]pyridine-3-carbaldehyde with different aryl
ketones in the presence of 40% alcoholic KOH.
SECTION-II : Synthesis and biological evaluation of 3-(1-Acetyl-3-aryl-4,5-
 dihydro-1H-pyrazol-5-yl)-2-(4-chlorophenyl)imidazo[1,2-a]pyridines
The pyrazoline derivatives of Type (II) have been synthesized by the reaction of
chalcones of Type (I) with hydrazine hydrate in glacial aceticacid.
PART-II : STUDIES ON CYANOPYRIDINES
Cyanopyridine derivatives represents one of the modest class of the compounds
possessing wide range of therapeutic activities such as anti-inflammatory, CNS depressant,













Type (I)  R = Aryl
3analgesic, antimicrobial and anticonvulsant. With a view to getting better therapeutic
agents and to evaluate its pharmacological profile, different types of cyanopyridine
derivatives have been synthesized which have been described as under.
SECTION-I : Synthesis and biological evaluation of 4 - [ 2 - ( 4 -Chlorophenyl)
 imidazo[1,2-a]pyridin-3- yl]-2- methoxy-6-arylnicotinonitriles
Cyanopyridines of Type (III) have been synthesized by the cyclocondensation of
chalcones of Type (I) with malanonitrile and sodium methoxide.
PART-III : STUDIES ON MANNICH BASES
Compound containig bridge N-atom exhibit pronounced pharmacological
activities. Mannich base derivatives with bridge N-atom have been found to be potent
drug in medicinal science and possess a wide range of therapeutic activities like
antihypertensive, antidepressant, anticholestemic, antifungal and antibacterial etc. By
considering this valid observations, we have synthesized some newer mannich bases,
which have been shown as under.










Type (III) R = Aryl
4Mannich bases of Type (lV) have been synthesized by the condensation of 2-(4-
chlorophenyl)imidazo[1,2-a]pyridine with different secondary amines and formaldehydes
in the presence of acid catalyst.
PART-IV : STUDIES ON ISOXAZOLES
Isoxazoles are of considerable chemical and pharmaceutical importance. Many
isoxazole derivatives have displayed diverse pharmacological activities.In view of our
on going interest in the synthesis of substituted isoxazoles, the synthesis of some new
potentially bioactive isoxazole derivatives have been under taken, which have been
described as under.
SECTION-I : Synthesis and biological evaluation of 2-(4-Chlorophenyl)-3-(3-
arylisoxazol-5-yl)imidazo[1,2-a]pyridines
Isoxazole derivatives of Type (V) have been prepared by the cyclocondensation
of chalcone of Type (I) with hydroxylamine hydrochloride in the presence of sodium













Type (lV)   R1, R2 = Aryl
Type (V)   R = Aryl
5PART-V : STUDIES ON OXOPYRIMIDINES
In view of powerful biological activities shown by oxopyrimidines like analgesic,
antidiabetic, insecticidal, antibacterial etc, it was thought worthwhile to synthesized some
new oxopyrimidine derivatives possessing better biological active value with least side
effect, which have been described in following section.
SECTION-I : Synthesis and biological evaluation of 6-[2-(4-Chlorophenyl)
 imidazo[1,2-a]pyridin-3-yl]-4-arylpyrimidin-2(1H)-ones
Oxopyrimidines of Type (VI) have been synthesized by the cyclocondensation of
chalcones of Type (I) with urea in the presence of basic catalyst.
PART-V : STUDIES ON ARYLAMINOMETHYL DERIVATIVES
Arylaminomethyl derivatives have been found to be potent drug in pharmaceuti-
cal and possess a wide range of pharmacological activities such as anticonvulsant, hyp-
notic, antithyroid, antihistamine etc. It appeared of interest to design and synthesize
arylaminomethyl derivatives, which have been described as under.









Type (VI)   R = Aryl
6Schiff bases of Type (VII) have been prepared by the condensation of 2-(4-
chlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde with different aromatic amines.
SECTION-II : Synthesis and biological evaluation of N-{[2-(4-Chlorophenyl)
   imidazo[1,2-a]pyridin-3-yl]methyl}-N- arylamines
The compound of Type (VIII) have been synthesized by the reaction of
compounds of Type (VII) with an. NaBH4
PART-V : STUDIES ON IMIDAZOLINONES
5-Oxoimidazolinone derivatives have been reported to be active as anticancer,
CNS depressant, sedative, anticonvulsant and as mono amino oxidase (MAO) inhibitor.
Considering these finding, we thought it worthwhile to synthesize some new imidazolinone













Type (Vll)   R = Aryl
Type (VIII)   R = Aryl
7SECTION-I : Synthesis and biological evaluation of (5Z)-5-{[2-(4-Chlorophenyl)
 imidazo[1,2-a]pyridin-3-yl]methylene}-3-aryl-2-phenyl-3,5-dihydro-
4H-imidazol-4-ones
The imidazolinones of Type (IX) have been synthesised by the reaction of
azalactone with different arylamine in pyridine.
[B] STUDSIES ON DIFLUOROBENZENE DERIVATIVES
Compounds bearing difluorobenzene nucleus are endowed with a variety of
therapeutical activities such as fungicidal, antimicrobial, antitubercular, hypnotic,
antitumor and herbicidal activity. Our efforts are focused on introduction of chemical
diversity in the molecular frame work in order to synthesizing molecule of widely
different composition.
Prompted by these facts, we have synthesized some pharmacologically active
cyanopyrans, pyrimidines and cyanopyridones bearing difluorobenzene nucleus.
PART-I : STUDIES ON CYANOPYRANS
Cyanopyran derivatives are the important class of therapeutic agents, which have
been deeply studied during search on new potential agents. They have been found to be
active as anticoagulant, analgesic, antimalarial and herbicidal agent. To approach this








Type (IX)   R = Aryl
8SECTION-I : Synthesis and biological evaluation of (2E)-1-(2,4-Difluorophenyl)-
3-arylprop-2-en-1-ones
The chalcone derivatives of Type (X) have been synthesized by the condensation
of 2,4-difluoroacetophenone with different aromatic aldehydes in the presence of 40%
alcoholic KOH.
SECTION-II : Synthesis and biological evaluation of 2-Amino-6-(2,4-difluorophenyl)
  -4-aryl-4H-pyran-3-carbonitriles
Cyanopyran derivatives of Type (XI) have been synthesized by the reaction of
chalcone of Type (X) with malanonitrile in basic catalyst.
PART-II : STUDIES ON PYRIMIDINES
Pyrimidines are biologically important compounds, their synthesis and chemistry
have received remarkable attention. Pyrimidine derivatives are found to possess most
effective therapeutic activities like anti-inflammatory, antiviral, antimalarial, herbicidal etc.
These finding prompted us to design and synthesized some pyrimidine











Type (X)   R = Aryl
Type (Xl)   R = Aryl
9SECTION-I : Synthesis and biological evaluation of 4-(2,4-Difluorophenyl)-6-
arylpyrimidin-2-amines
Aminopyrimidine derivatives of Type (XII) have been synthesized by the
condensation of chalcones of Type (X) with guanidine hydrochloride in presence of  basic
media.
SECTION-II : Synthesis and biological evaluation of 4-(2,4-Difluorophenyl)-6-
  arylpyrimidine-2(1H)-thiones
Pyrimidinethione derivatives of Type (XIII) have been synthesized by the
cyclocondensation of chalcones of Type (X) with thiourea in presence of basic catalyst.
PART-III : STUDIES ON CYANOPYRIDONES
Cyanopyridone derivatives are of considerable interest due to many therapeutic
activities which they possess such as antimicrobial , fungicidal, analgesic, antidiabetic,
herbicidal and sedatives etc. In order to develop medicinally important compounds, we













Type (XIII)   R = Aryl
Type (XII)   R = Aryl
10
SECTION-I : Synthesis and biological evaluation of 4-(2,4-Difluorophenyl)-6-
aryl-2-oxo-1,2-dihydropyridine-3-carbonitriles
Cyanopyridone derivatives of Type (XIV) have been prepared by the reaction of
chalcones of Type (X) with ethyl cyano acetate and ammonium acetate.
The constitution of all above products has been supported by elemental analysis
and spectral studies like IR, 1H NMR and mass spectroscopy. The purity of the






NType (XIV)   R = Aryl
11
 In vitro studies on multiple biological activities.
 (I) Selected compounds have been evaluated for their in vitro biological assay like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv
at a concentration of 6.25 µg/ml using Rifampin as standard drug, which
have been tested by Tuberculosis Antimicrobial Acquisition Co-ordinating
Facility (TAACF), Alabama, U.S.A.
 (II) Al l  the  compounds  have been a lso  evaluated for  thei r  ant ibacter ia l
activity towards Gram positive and Gram negative bacterial strains and
ant i fungal  ac t iv i ty  towards  Aspergi l lus  niger at  a  concentra t ion of
40 µg/ml. The biological activity of the synthesized compounds have been









Research programs for the discovery of new drugs and for improving the
evolution criteria are under way in many laboratories. In addition knowledge of specific
constituents of the mycobacterium cell and their biochemical roles has advanced
considerably in the recent years and may permit a more rational approach to the design
of new drug action on specific targets. Also, recent improvements in the knowledge of
the mechanism of action of available drugs and the biochemical mechanism of resistance
to them may be used as a basis for design new and better weapons to fight the
mycobacterial diseases.
The last few decades have witnessed massive advances in biochemistry,
physiology, pharmacology and genetics. This has to a better understanding of working
the body at the molecular level. This in turn has resulted a much better understanding of
the structure and function of important drug targets e.g. enzymes and receptors and that
how drugs can be designed for these targets.
Advances in organic chemistry have made possible the synthesis of complexes
molecules. Enantiometry is an important process in medicinal chemistry since life is
inherently chiral and the drug targets within the body are chiral. As such, they can
distinguish between the enantiomers of a chiral drug, so the use of recemic drug is
inherently wasteful, since only one enantiomer is ideally designed to interact with its
target. Moreover, the existences of the “wrong” enantiomer could create problems if it
interacted wtih a different receptor, resulting inside effects.
A prerequisite for the design of safe drugs is knowledge about the various
metabolic reactions that xenobiotics and endogenous compounds undergo in the
organism. Because pharmacological activity depends on molecular structure, the
medicinal chemist is restricted in the choice of functional groups for the design of new
Studies on Chemical Entities....
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drugs. Often he finds or she encounters a situation where a structure has adequate
pharmacologic activity but has an inadequate pharmacokinetic profile (i.e., absorption,
distribution, metabolism and excretion). This is because pharmacology and
pharmacokinetic departments in the pharmaceutical industry often do not collaborate at
the early stage of drug development. It is only later, when the new compound is tested in
animals or in humans, that pharmacokinetic disadvantages become obvious.
Modern drug discovery starts with the identification of a pharmacologic target
that is hypothetically the primary cause of disease. Potential targets include host cell
genes, receptors, signaling systems, organelles and biochemicals such as enzymes.
Additionally, an element of a disease modifying process, such as antiinflammatory
mediator, may be a target. Biological processes required for propagation of infectious
agents have also proven to be therapeutically useful targets; examples include protease
and reverse transcriptase of the human immuno deficiency virus (HIV). Common to all
targets selected as therapeutic opportunities is the hypothesis that some type of
pathogenetic linkage exists to the disease causing process, rather than to specific signs,
symptoms, or effects.
Heterocyclic compounds have great applicability in pharmaceutics because they
have specific chemical reactivity and provides false synthons in biosynthetic process or
block the normal functioning of biological receptors. The inhibition of amide resonance
resulting into more susceptibility of-lactam to nucleophile is considered at least in part
responsible for antibacterial property, apparently by acetylating transpeptidase and thus
inhibiting bacterial cell wall biosynthesis.
Most of the alkaloids which are nitrogenous bases occurring in plants and many
antibiotics including penicillin and streptomycin have also heterocyclic ring system. Many
natural pigments such as indigo, haemoglobin and anthocyanin are heterocycles.
Studies on Chemical Entities....
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Most of the sugars are their derivatives including Vitamin C for instance, exist largely in
the form of five membered. Vitamin B6 (Pyridoxine) is a derivative of pyrimidine essential
in aminoacid metabolism.
Important drugs, poisons and medicines (both natural and synthetic) such as
sulphathiazole, pyrenthrin, rotenmone, alpidem, zolpidem, fluconazole, strychnine,
reserpine, certain of the antihistamines, the ergot alkaloids caffeine, cocaine, barbiturates,
etc. are heterocyclic compounds.
The ultimate product of a successful drug design effort. Our goal for this is
to begin to deconvolute this information in order to apply it to design of new drugs.
Taking in view of the applicability of heterocyclic compounds, we have undertaken
the preparation of heterocycles bearing imidazo[1,2-a]pyridine nucleus and difluoro
benzene nucleus. The placement of a wide variety of substituents of these nuclei have
been designed in order to evaluate the synthesized products for their pharmacological
profile against several strains of bacteria and fungi.
AIM AND OBJECTIVES
In the pharmaceutical field, these have always been and will continue to be a ned
for new and novel chemical inhibitors of biological function. Our efforts are focused on
the introduction of chemical diversity in the molecular fram work in order to synthesizing
pharmacologically interesting compounds of widely different composition.
During the course of our research work, looking to the application of
heterocyclic compounds, several entities have been designed, generated and
characterized using spectral studies. The details are given as under.
1. To synthesize therapeutically active compounds like pyrazolines, cyanopyridines,
mannich bases, isoxazoles, oxopyrimidines, arylaminomethyl derivatives,
Studies on Chemical Entities....
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imidazolinones bearing imidazo[1,2-a]pyridine moiety and cyanopyrans,
pyrimidines and cyanopyridones bearing difluorobenzene nucleus.
2. To characterize these products for structure elucidation using several
spectroscopic techniques like IR, 1H NMR and Mass spectral studies.
3. To assess the reaction and purity of the compounds were done by TLC.









Bridge nitrogen containing fused heterocycles represents important building
blocks in both natural and synthetic bioactive compounds which have been shown to
possess diverse therapeutic activities1. Hence they are interesting target to be prepared
to our research on medicinally interesting heterocyclic entities. Aza-indolizine are of two
types, imidazo[1,2-a]pyridine (I) and imidazo[1,5-a]pyridine (II).
The aza-indolizine contains a phenyl ring fused to a imidazole ring is indicated in
the structure, hence it is also known as imidazo[1,2-a]pyridine2. Several procedure for
their synthesis have been extensively studied. Such studies have been stimulated by various






The constitution of imidazo[1,2-a]pyridine was reviewed by W. L. Mosby3 in
1961. Imidazo[1,2-a]pyridine derivatives not only known for their pharmacological
applications, they are also used in disperse dyes4.
SYNTHETIC ASPECT
Classical methods have been reported in the literature for the synthesis of
imidazo[1,2-a]pyridines. The procedure for synthesizing imidazo[1,2-a]pyridines have
been described as under.
1. The synthes i s of imidazo[1 ,2-a]pyr id ine  f rom 2-aminopyridine with
ω-bromoacetophenone was reported by Tsch i t sch ibab ine 5.
  (I)                                     (II)
Studies on Chemical Entities....
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2. 2-Acetylimidazo[1,2-a]pyridine6 can be constructed by the cyclocodensation
of 2-aminopyridine with bromo butanedione.
3. Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent elimination
of nitrogens  give the imidazo[1,2-a]pyridine7.
4. Condensation of ethyl-6-aminonicotinate with chloroacetaldehyde according
to Hand’s procedure gave imidazo[1,2-a]pyridine-6-carbaldehyde8.
5. Paudler et al.9 have synthesized 5-amino-3-formylimidazo[1,2-a]pyridine from
acid catalyzed hydrolysis of 1,4-diazacycl[3,2,2]azine.
     6.      Imidazo[1,2-a]pyridine10 nucleus can be also synthesized by the reaction of




















































7. Tsai et al.11 have been prepared 3-amino imidazo[1,2-a]pyridine derivatives by
a three component condensation reaction between 2-aminopyridine, aldehyde














8. Groziak et al.12 have synthesized substituted imidazo[1,2-a]pyridine derivatives
















            The majority of imidazo[1,2-a]pyridine (VI) have been prepared by the reaction
of 2-aminopyridine (III) with a α-halocarbonyl compound (IV) which form oniumhalide




























 (III)              (IV)                               (V)                                 (VI)




Imidazo[1,2-a]pyridines are potential bioactive agents due to their wide spectrum
of therapeutic importance. A large number of substituted imidazo[1,2-a]pyridine
derivatives are prepared and tested for varieties of biological activities such as,
1. Anti-inflammatory, analgesic, antipyretic13,14
2. Antiviral15,16
3. Antianxiety17
4.      Antiulcer18,19
5.      Antifungal agents20
6.      Anthelmintic21
7.      Antibacterials22,23
8.      Hypnotic24
9.      Antiherpetie25,26
     10.      Gastric antisecretory27,28
     11.      Hypnoselective and anxioselective29
     12.      b-Amyloid formation inhibitors30
     13.      Benzodiazepine receptor agonists31
               14.      Nonsedative anxiolytic32
     15.      Active nonpeptide bradykinin B2 receptor antagonists
33
                16.     Cardiotonic agents34
      17.     Anticytomegalo-zoster and antivaricellazoster virus35-37
                18.     Long-acting local anesthetic38
                19.     Calcium channel blockers39
Alexander C. Humphries and co-workers40 have synthesized 8-fluoro
               imidazo[1,2-a]pyridine derivatives (VII) and evaluated as a bioisosteric replacement
               for imidazo[1,2-a]pyridine in an allosteric modulator ligand of the GABAA receptor.
               Kristjan S. Gudmundsson and co-workers41 reported the synthesis and antiviral activity
              of newer Erythrofuranosyl imidazo[1,2-a]pyridine C-nucleosides. I. Aramori et al.42
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Several imidazo[1,2-a]pyridine nucleus already in market which include alpidem43
[a ligand of both the central benzodiazepine receptors and the peripheral type
(Mitochondrial) benzodiazepine receptor] has sedative and anxiolytic properties and
zolpidem43 [a selective ligand for the central benzodiazepine receptor] is a hypnotic
drug. Both alpidem and zolpidem have higher affinity for benzodiazepine-1 than for
benzodiazepine-2 receptors44 and their interaction with various receptor has been
reported45.
James J. Kaminski and co-workers46 have investegated imidazo[1,2-a]pyridine
derivative 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine (IX) for
an antiulcer activity. On the basis of the reported metabolism of zolimidine, they
reported that the 3-cyanomethyl and 8-phenylmethoxy group have been established as
metabolic sites.
have been synthesized imidazo[1,2-a]pyridine derivatives which are highly potent and


















































                     (IX)     Zolimidine
Brian A. Johns et al.47 and Chaouni-Bendallah  A. et al.48 synthesized  a novel
imidazo[1,2-a]pyridines (X) with potent  activity against Herpes Simplex viruses. Sophic
Ceard and co-workers49 have synthesized some newer imidazo[1,2-a]pyridine derivatives (XI)
as bioactive agent. Imidazo[1,2-a]pyridine units appear as important building blocks in
both natural and synthetic bioactive compounds50-52 and recognition on DNA binding and
to yield different pharmacokinetic profile.
Mohamed A. Ismail and co-workers53 have synthesized some newer diamine
imidazo[1,2-a]pyridine (XII), 5,6,7,8-tetrahydo imidazo[1,2-a]pyridines and their
corresponding N-hydroxy and N-methoxy analogues and evaluated against
Trypanosoma b. rhodesiense (T. B. rhodesiense) and Plasmodium falciparum
(P. falciparum). Aromatic diamidines exhibit broad spectrum antimicrobial activity
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a - R: H
b - R: Me
 (XII)
Thus the important role displayed by imidazo[1,2-a]pyridine and its derivatives
for various therapeutic and biological activities prompted us to synthesize some Chalcones,
Acetyl pyrazolines, Cyano pyridines, Thiopyrimidines, Oxopyrimidines, Mannich bases
Isoxazoles, Schiff bases, Imidazolnone derivatives bearing Imidazo[1,2-a]pyridine  moiety
in order to achive compounds having better therapeutic activities described as in the
following parts.
[A]    STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
PART-I    : STUDIES ON PYRAZOLINES
PART-II   : STUDIES ON CYANOPYRIDINES
PART-III : STUDIES ON  MANNICH BASES
PART-IV  : STUDIES ON ISOXAZOLES
PART-V   : STUDIES ON OXOPYRIMIDINES
PART-VI  : STUDIES ON ARYLAMINO METHYL DERIVATIVES
PART-VII: STUDIES ON IMIDAZOLINONES
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INTRODUCTION
The growing potent literature of recent years demostrate that chalcone being a
very active intermediate through which novel heterocycles with promissing biological
profile can be designed. The term chalcone was first coined by Kotanecki and Tambor1
who did pioneering work in the synthesis of natural colouring compounds. They are
characterized by their possession of C6(A)-CO-CH=CH-C6(B), structure in which two
aromatic ring A and B, are linked by an aliphatic three carbon chain.
Chalcones are phenyl stryl ketones containing reactive keto-ethylinic group
(-CO-CH=CH-). Chalcones are also known as benzalacetophenones or benzylidene
acetophenones the alternative name given to chalcones are  β-phenyl acrylphenone,
γ-oxo-α, γ-diphenyl-α-propylene and α-phenyl-β-benzoethylene.
SYNTHETIC ASPECT
A considerable variety of methods are available in literature for the synthesis of
chalcones. The most convenient method is the one, that involves the Claisen-Schimidt
condensation of equimolar quantities of an aryl methyl ketones with arylaldehyde in
presence of alcoholic alkali.2
Several condensing agents used for the synthesis of chalcones are alkali of different
strength3,4 hydrochloric acid5,6, phosphorous oxychloride7, piperidine8, anhydrous
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MECHANISM
The following mechanisms have been suggested for the synthesis of
chalcones.
The  in te rmed ia te  aldo l  type  p roduc t s  fo rmed  read i ly  undergoes
dehydration even under mild condition, particularly when R and R’ are aryl groups.
REACTIVITY OF CHALCONES
The chalcones have been found to be useful for the synthesis of variety of
heterocyclic compounds are as under.
(a) Pyrazolines14 and their derivatives can be prepared by the condensation
of chalcones with hydrazine hydrate and acetic acid.
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(d) Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyanopyridines.16
(e) Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords
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pyridopyrimidines.17
(f) Isoxazoles18 can be prepared by the reaction of chalcones with hydroxylamine
hydrochloride and sodium acetate.
(g) Chalcones on treatment with urea in presence of alkali  affords 2-oxo
pyrimidines.19
(h) Chalcones on reaction with thiourea in presence of alkali/acid yields
2-thiopyrimidines.20
(i) Chalcones on treatment with guanidine hydrochloride in presence of alkali
affords 2-aminopyrimidines.21
(j) Cyanopyridone22 derivatives can be prepared by the condensation of chalcone
with ethyl cyanoacetate.
(k) Chalcones react with monoethanolamine in ethanol gives 1,4-oxazipines.23
(l) Oxirane24 can be prepared by the reaction of chalcone with H2O2 in basic
media.
(m) Chalcones on reaction with barbituric acid gave barbitone25 derivatives.
(n) Chalcone gives imine derivatives with amine in presence of sulfuric acid as
catalyst.26
(o) Chalcones on condensation with malononitrile in pyridine forms 2-amino-3-
cyanopyrans.27
(p) Chalcones react with P2S5 yielded 2-isothiazolidines.
28
(q) Chalcones react with sodium nitrile in presence of glacial acetic acid in ethanol
 produces 2-1H-pyrimidines.29
(r) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-thiazepines.30
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THERAPEUTIC IMPORTANCE
Chalcone derivatives have been found to possess wide range of therapeutic















Aldose reductase inhibitor activity of chalcone derivatives have been reported by
Okuyama et al.50 They are also associated with antitumor and antifungal activity as
reported by A. Tsotitns and coworkers.51 Antifeedant activity of chalcones have been
observed by Sharma and Sreenivasulu.52
Ezico et al.53 have demonstrated that chalcone possess a valuable antiproliferation
activity both on sensitive cancereous cell and on cell which are resistant to common
chemotherapeutic drugs. Some of the chalcones have been  patented for their use in
treatment of glucoma54 and showed antifungal55,56, aldose reductase inhibitors57,
anticancer58 and antimicrobial59,60 activities.
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Bartira Rossi-Bergmann et al.61 have synthesized novel chalcone analougs (II)
with antileishmanial activity. Analougs containing nitro, fluorine or bromine group
respectively displayed increased selectivity against the parasites as compared with natural
chalcone.
      (II)
Recently Ni Liming et al.62 have synthesized chalcones and screened for their
antiinflammatory and cardiovascular activity. Kumar Srinivas et al.63 have synthesized
chalcones as a antitumor agent. Ko Horng-Huey et al.64 have prepared chalcones as
antiinflammatory agent. Nakahara Kazuhiko et al.65 have synthesized chalcones and tested
as carcinogen inhibitors. Antitubercular agents of chalcone derivatives have been prepared
by Lin Yuh-Meei et al.66
Das B. P. et al.67 have found that chalcones possesses larvicidal properties. Kim
Min-Young et al.68 have synthesized chalcones and tested for their matrix
metalloproteinase inhibitor activity. Satyanarayana M. et al.69 have synthesized chalcone

















      (III)
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Prem P. Yadav and co-workers70 have synthesized nitrogen and sulfur containing
furanoflavonoids and thiophenylflavonoids (IV), which have been screened for
antifungal and antibacterial activity. Meng C. Q. et al.71 discovered some novel hetero













            (V)
Dong Hwan Shon et al.72 have synthesized and investigated the anti-
inflammatory activity of 2,4,6-tris(methoxymethoxy)chalcone derivatives.
Liu Mei et al.73 have prepared chalcones and screened for antimalarial activity. Opletalova
Veronika et al.74 have synthesized chalcones and tested as cardiovascular agents.
Moreover, it has been found that chalcone derivatives possesses nitric oxide inhibitor,75,76
anti HIV77,78 and antiproliferative79,80 activities.
Furthermore, Alcaraz M. J. et al.81 have described the role of nuclear
factor-kappa B and heme oxygenase-1 in the action of an anti-inflammatory chalcone
derivative in RAW 264.7 cells. Nerya O. et al.82 have prepared some new chalcones as
potent tyrosinase inhibitors (VI).
     (IV)
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Moreover, Khatib S. et al.83 synthesized some novel chalcones as potent
tyrosinase inhibitors (VII). Ko H. H. et al.84 have prepared some new chalcones for
potent inhibition of platelet aggregation. Ziegler H. L. et al.85 reported chalcones as an
antiparasitic. Go M. L. et al.86 have described the synthesis and biological activities of
chalcones as antiplasmodial. A new class of sulfonamide chalcones (VIII) synthesized

















R=4 or 3,4-OH (VIII)
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N. Lal l  and co-workers88 have synthesized 2’ ,4’ ,6’- t r ihydroxy-3’-
phenylchalcone and 4’,6’,5”-trihydroxy-6”,6”-dimethyldihydropyrano[2”,3”-2’,3’]
chalcone as an antiviral and antitubercular agents. M. L. Ferrnandiz et al.89 have
synthesized phenylsulphonylurenyl chalcone derivatives with various patterns of
substitution and tested for their effect on nitric oxide (NO) and prostaglandin
E2(PGE2)overproduction in RAW 264.7 macrophages. Several derivatives selectively
inhibited cyclo-oxygenase-2 (COX-2) activity in human monocytes. C. C. Lin et al.90
have examined 1,3-diphenyl-2-propenone for its effect on proliferation in human breast
cancer cell lines, MCF-7 and MDA-MB-321.
Chalcones have been proved to be an important intermediate for the synthesis of
many heterocyclic compounds in organic chemistry. These facts pormpted us to sythesize
some new chalcone derivatives bearing imidazo[1,2-a]pyridine nucleus, in order to
achiving better therapeutic agents described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF (2E)-3-[2-
 (4-CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-1-
 ARYLPROP-2-EN-1-ONES
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INTRODUCTION
Amongst nitrogen containing five membered heterocycles, pyrazolines have
proved to be the most useful framework for biological activities. Pyrazolines have
attracted attention of medicinal chemists for both with regard to heterocyclic chemistry
and the pharmacological activities associated with them.
In 1967 Jarobe, reviewed the chemistry of pyrazolines, which have been studied
extensively for their biodyndmic behaviour91 and industrial applications.92 Led by these
findings it appeared of interest to synthesize newer acetyl pyrazoline derivatives bearing
imidazo[1,2-a]pyridine nucleus with better potency.
SYNTHETIC ASPECT
Different methods for the preparation of 2-pyrazoline derivatives  documented in
literature are as under.
1. 2-Pyrazolines synthesized by the cycloaddition of diazomethane with
substituted chalcones.93
2. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromide
with hydrazine.94
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4. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile and the
N-aryl maleimides yields the corresponding pyrazolines.96
5. Epoxidation of chalcones i.e. epoxy ketones which reacted with hydrazine and
phenyl hydrazine to give pyrazolines.97
Furthermore, B. Gyassi et al.98 investigated the one pot synthesis of some
pyrazolines in dry media under microwave irradiation. S. Paul et al.99 and Dandia Anshu
et al.100 have also described the microwave assisted synthesis of 2-pyrazolines.
MACHANISIM
The following mechanism seems to be operable for the condensation of chalcones
with hydrazine hydrate.101
Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system (I) forms species (II), in which the negative charge is mainly accomodated by the
electronegative oxygen attom.
Proton transfer from the nitrogen to negative oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intramolecular nucleophilic
attack by the primary amino group of ketoamine on its carbonyl carbon followed by
proton transfer from nitrogen to oxygen leads ultimately to carbonyl amine (IV). The
later with a hydroxy group and amino group on the same carbon lose water molecule to































  (I) (II) (III)
(IV)  (V)
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THERAPEUTIC IMPORTANCE


















E. Palaska et al.122 have prepared 3,5-diphenyl-2-pyrazolines (III) and cited their
antidepressant activity. B. Shivrama et al.123,124 have synthesized pyrazolines as
antibacterial agents. Hiremath S. P. et al.125 have reported pyrazolines as analgesics,
antiinflammatory and antimicrobial agents. Goodell et al.126 have synthesized some newer
1,3,5-trisubstituted pyrazoline derivatives which shows anti westnile virus activity (IV).
F. Manna and co-workers127 have described 1-acetyl-5-(2'-bromophenyl)-4,5-dihydro-
3-(2'-hydroxyphenyl)-1H-pyrazoline and its derivatives which acts as potent bioactive
agents.
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.
Udupi R. H. and Bhatt A. R.128 have reported the synthesis and biological activity
of Mannich bases of certain 1,2-pyrazolines. Nugent Richard129 investigated pyrazolines
bis phosphonate ester as novel antiinflammatory and antiarthritic agent. Fuche Rainer et
al.130 have prepared some new 1H-pyrazoline derivatives (V) and reported them as
pesticides. Furthermore, Tsubai et al.131 have synthesized some new (phenylcarbamoyl)
pyrazolines (VI) as an insecticides and at 40% concentration shows 100% mortality of










       (III)       (IV)












Moreover, T. M. Stivensen et al.132 have also investigated N-substituted pyrazoline
type insecticides. Tanka Katsohori133 have patented pyrazoline derivatives as herbicides
and Johannes et al.134 as insecticides. Moritaz Z. and Hadol135 investigated a semi emperial
molecular orbital study on the reaction of aminopyrazolinyl azodye with singlet
molecular oxygen. Shivnanda M. K. and co-workers136 have prepared substituted
pyrazolines and reported their antibacterial activity.
Abdalla M. M. et al.137 have synthesized pyrazolines and tested their for
antiandrogenic activity. Berghot M. A. et al.138 have synthesized pyrazolines as
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antibacterial agents. Maurer Fritz et al.139 have synthesized pyrazoles and screened for
their pesticidal activity.
S. S. Sonarc et al.140 have synthesized-3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines and tested their antimicrobial activity. H. S. Joshi141 et
al. have also synthesized some new pyrazolines as an antimicrobial agent. G. N. Mishirika
et al.142 have prepared 2-pyrazolines of salicyclic acid  possessing antimicrobial
properties. Tunfawy Atif and co-workers143 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agents.
This, significant biological  properties associated with pyrazoline derivatives have
aroused considerable interest to design the compounds with better drug potentials and
to study their pharmacological profile, which have been described as under.
SECTION-II :SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(1-
 ACETYL-3-ARYL-4,5-DIHYDRO-1H-PYRAZOL-5-YL)-2-
 ( 4 - C H L O R O P H E N Y L ) I M I D A Z O [ 1 , 2 - a]PYRIDINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF (2E)-3-[2-(4-CHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-1-ARYLPROP-2-EN-1-ONES
With the biodynamic activities of chalcones and it is a good synthon for various
heterocyclic rings, the interest has been focussed on the synthesis of new chalcones.
With a view to obtained compounds having better therapeutic activity, we have synthesized
(2E)-3-[2-(4-chloro phenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones by
the condensation of 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde with
various aromatic ketones in presence of catalytic amount  of alkali.
The constitution of the synthesized products have been characterized by using
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesized compounds were compared with standard drugs.
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Reaction Scheme
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Gram positive bacteria : Staphylococcus aureus
Bacillus Coccus
Gram negative bacteria : Pseudomonas aeruginosa
Aerogenes
Fungi : Aspergillus niger
Concentration           : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzyl Penicillin,
Ciprofloxacin, Erythromycin,
Greseofulvin
The antimicrobial activity was compared with standard drug viz  Amoxicillin, Benzyl
Penicillin,  Ciprofloxacin, Erythromycin and antifungal activity was compared with viz
Greseofulvin. The inhibition zones measured in mm.
MICROBIOLOGICAL EVALUATION
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 Observed
Alkane C-H str. (asym.) 2982 2975-2950        144
-CH3 C-H str. (sym.) 2864 2880-2860  ,,
C-H i.p.def. (asym.) 1450 1470-1435  ,,
C-H o.o.p. def. (sym.) 1362 1390-1370  ,,
Aromatic C-H  str. 3067 3090-3030        145
C=C str. 1509 1540-1480  ,,
Imidazo[1,2-a] C=N str. 1604 1612-1593  ,,
pyridine C-N str. 1170 1220-1020  ,,
α,β-unsaturated C=O str. 1655 1700-1640        144
ketone C=C str. 1559 1580-1550  ,,
Vinyl CH=CH str. 3017 3050-3000  ,,
Ether C-O-C str. 1221 1260-1200  ,,
Halide C-Cl str. 796 800-600  ,,
Type        Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF (2E)-3-[2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range :
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1 3.84 3H singlet Ar-OCH3     -
2 6.62 2H doublet Ar-H(a,a’) J=9.6
3 6.75-6.78 2H doublet Ar-H(b,b’) J=9.0
4 6.90-6.93 1H doublet -CH(c) J=9.3
5 7.22-7.36 4H multiplet Ar-H(g,h,i,j)     -
6 7.56-7.59 1H doublet -CH(d) J=9.7




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF (2E)-3-[2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
Studies on Chemical Entities....







































































































Studies on Chemical Entities....
                            Pyrazolines...
46
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF (2E)-3-[2-(4-CHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-1-ARYLPROP-2-EN-1-ONES
[A] Synthesis of  2-(4-Chlorophenyl)imidazo[1,2-a]pyridine
          A solution of 2-amino pyridine (23.5 gm, 0.25 mol) in DMF(100 ml) was added
to 2-chloro-1-(4-dichlorophenyl)ethanone (18.9 gm, 0.1 mol) and the reaction mixture
was refluxed with stirring for 6 hour. Cool the content, the solid seperated was filtered
and dried in vacuo. Yield 68%, m.p192oC, Anal. Calcd. for C13H9ClN2: Require: C,
68.28, H, 3.97, N, 12.25 % ; Found: C, 68.26, H, 3.96,  N, 12.24 %.
[B] Synthesis of  2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-carbaldehyde
           To a well stirred solution of phosphorus oxychloride (11 ml), chloroform (32 ml)
and DMF(8 ml) maintained at 0-10oC. was added slowly to a solution of 2-(4-
chlorophenyl)imidazo[1,2-a]pyridine (4.56 gm, 0.02 mol) in chloroform (140 ml). The
mixture so  obtined was refluxed for 8 hr., the solution was evaporated to dryness in
vacuo. the residue was treated with cold water and filtered and crystallized from methanol.
Yield 64%, m. p. 196oC , Anal. Calcd. for C14 H9 Cl N2O Require: C, 65.51, H, 3.53, N,
10.91 %; Found: C, 65.50, H, 3.52, N, 10.90 %.
[C] Synthesis of (2E)-3-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-(4-
methoxyphenyl)-prop-2-en-1-one
To a solution of 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde (2.56
gm, 0.01 mol), p-methoxyacetophenone (1.5 gm, 0.01 mol) in ethanol (25 ml) and 40%
NaOH solution was added till the solution become basic. The reaction mixture was
stirred for 24 hrs. The content was poured on to crushed ice. Upon neutralization the
solid separated was crystallized from ethanol. Yield 67%; m.p.214oC. Anal. Calcd. for
C23H17ClN2O2; Required : C, 71.04; H, 4.41; N, 7.20%; Found: C, 70.98; H, 4.40; N,
7.19%.
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Similarly other  (2E)-3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
arylprop-2-en-1-ones were prepared. The physical data are recorded in Table No. 1.
[D] Biological evaluation of  (2E)-3-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-
3-yl]-1-arylprop-2-en-1-ones
(a) Antibacterial activity
The purified products were screened for their antibacterial activity using
cup-plate agar diffusion method. The nutrient agar broth prepared by the usual method
was inoculated aseptically with 0.5 ml of 24 hr. old subcultures of Bacillus coccus,
Staphylococcus aureus, Aerogenes, Pseudomonas aeruginosa in separate conical
flasks at 40-500C and mixed well by gentle shaking. About 25 ml content of the flask
was poured and evenly spreaded in a petridish (13 cm diameter) and allowed to set for
2 hr. The cups (10 mm diameter) were formed by the help of borer in agar medium and
filled with 0.04ml (40mg) solution of sample in DMF.The plates were incubated at 370C
for 24 hr. and the control was also maintained with 0.04ml of DMF in a similar manner
and the zone of inhibition of the bacterial growth were measured in millimeter and recorded
in Graphical Chart No. 1
(b) Antifungal activity
Aspergillus niger was employed for testing antifungal activity using cup-plate
agar diffusion method. The culture was maintained on sabourauds agar slants sterilized
sabourauds agar medium was inoculated with 72 hr. old 0.5ml suspension of fungal spores
in a separate flask. About 25 ml of the inoculated medium was evenly spreaded in a
petridish (13cm diameter) and allowed to set for 2 hr. the cups (10mm diameter) were
punched. The plates were incubated at 30 0C for 48 hr. After the completion of incubation
period, the zone of inhibition of growth n the form of diameter in mm was measure.
Along the test solution in each petridish one cup was filled up with solvent, which acts as
control. The zone of inhibition of test solution  are recorded in Graphical Chart No. 1
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(1-ACETYL-3-ARYL-
4,5-DIHYDRO-1H-PYRAZOL-5-YL)-2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDINES
Pyrazolines play a vital role owing of their wide range of biological activity and
with an aim to getting better drug, it was considered worthwhile to synthesize some new
acetyl pyrazolines. The preparation of  3-(1-acetyl-3-aryl-4,5-dihydro-1H-pyrazol-5-
yl)-2-(4-chlorophenyl)imidazo[1,2-a]pyridines Type (II) have been undertaken by
cyclocondensation of chalcones of Type (I) with hydrazine hydrate in glacial acetic acid.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2969 2975-2950 144
-CH3 C-H str. (sym.) 2853 2880-2860   ,,
C-H def. (asym.) 1453 1470-1435   ,,
C-H def. (sym.) 1392 1390-1375   ,,
Aromatic             C-H  str. 3067 3090-3030 145
C=C str. 1473 1540-1480   ,,
Imidazo[1,2-a] C=N str. 1601 1612-1593   ,,
pyridine C-N str. 1089 1220-1020   ,,
Pyrazoline C=O str. 1651 1612-1700 145
C=N str. 1610 1612-1593   ,,
N-H str. 3428 3400-3200   ,,
Ether C-O-C str. 1248 1260-1200   ,,
Halide C-Cl str. 741 800-600 144
IR SPECTRAL STUDIES OF 3-(1-ACETYL-3-(4-METHOXYPHENYL)-4,5-
DIHYDRO-1H-PYRAZOL-5-YL)-2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.38 3H singlet Ar-CH3                -
2 3.41-3.47 1H dd Ar-H(c)                -
3 3.68-3.74 1H dd Ar-H(d)                -
4 6.06-6.13 1H dd Ar-H(e)                -
5 6.77-6.81 1H doublet Ar-H (l)             J=9.1
6 7.16-7.25 4H multiplet Ar-H(f,g,h,i)          -
7 7.360--7.388 2H doublet Ar-H(a,a')          J=8.4
8 7.59-7.64 1H dd Ar-H(k)         J=11.0,J=2.3
9 7.82-7.84 2H doublet Ar-H(b,b')         J=9.0




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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     EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-(1-ACETYL-3-ARYL-
4,5-DIHYDRO-1H-PYRAZOL-5-YL)-2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDINES
[A] Synthesis of (2E)-3-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
arylprop-2-en-1-ones
See Part-I [A], Section-I [C].
[B] Synthesis of 3-(1-Acetyl-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-
yl)-2-(4-chlorophenyl)imidazo[1,2-a]pyridine
A mixture of (2E)-3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-(4-
methoxyphenyl)-prop-2-en-1-one (3.88 gm, 0.01 mol) and hydrazine hydrate (0.5 gm,
0.01 mol) in glacial acetic acid (25 ml) was refluxed for 8 hour. The product was  isolated
and crystallized from ethanol. Yield 65%, m.p. 223oC, Anal. Calcd. for C25H21ClN4O2;
Requires: C, 67.49; H, 4.76; N, 12.59 %; Found: C, 67.46; H, 4.75; N, 12.58 %.
Similarly, other 3-(1-acetyl-3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-2-(4-
chlorophenyl)imidazo[1,2-a]pyridines were prepared. The physical data are recorded
in Table No.2
[C] Biological evaluation of  3-(1-Acetyl-3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-
2-(4-chlorophenyl)imidazo[1,2-a]pyridines
Antimicrobial testing were carried out as described in Part-I [A], Section-I [D].
The zones of inhibition of test solutions are recorded in Graphical Chart No.2
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INTRODUCTION
Much interest have been focused around cyanopyridine derivatives because of
their wide variety of pharmacological properties and industrial applications. Interest in
the synthesis of multicyclic pyridine containing compounds have increased in recent years
because of their biological and pharmacological activities. Although many substituted
pyridine compounds like other heterocyclic compounds are synthesized with their
functional group present from a cyclic compounds. The simple pyridine compounds are
prepared by the cyclization of aliphatic raw material.
The pyridine nucleus is found in a large number of commonly used drugs which
have diverse pharmacological activities. In our continuation work in the chemistry of




Different method for the preparation of 3-cyanopyridines are cited in literature.1-7
The well known methods are:
1. J. M. Babbit et al.8 have synthesized 3-cyano pyridines by cyclocondensation
of cyanoacetamide with ethyl acetoacetate in presence of base.
2. Samour and co-workers9 have prepared substituted cyanopyridines by
the condensation of chalcones with malononitrile in presence of ammonium
acetate.
3. Sakuri and Midorikaw10,11 have reported that malononitrile reacts with
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4. Matthew D. Bowman et al.12 have synthesized fluorescent cyanopyridine and
deazalumazine dyes using small molecule macroarrays.
MECHANISM
The reaction proceeds through conjugate addition of active methylene compounds
to the α,β-unsaturated system as shown below.
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THERAPEUTIC IMPORTANCE
The extensive use of cyanopyridine derivatives have been established in medicine










Abd El-Galil and co-workers22 have prepared 3-cyanopyridines (II) and studied
their pharmacological activity. Gadaginamath and co-workers23 have synthesized various
















           (II)  (III)
Many natural occurring and synthetic compounds containing the pyridine
scaffold possess interesting pharmacological properties24. Among them, 2-amino-3-
cyanopyridines have been identified as IKK-2 inhibitors25.
Studies on Chemical Entities....
                      Cyanopyridines...
69
Marco J.  L.  et  al . 26 have synthesized cyanopyridine derivatives as
acetylcholinesterase inhibitors. Moustafa M. A. et al.27 have prepared cyanopyridines
as antibacterial agents. Eduardo H. S. Sousa et al.28 documented thionicotinamides
coordinated to the a model system for the in vitro activation of thioamides
antituberculosis drugs. Rosentreter Ulrich et al.29 have synthesized a new cyanopyridine
(IV) as receptor agonists in the treatment of cardiac or urogenital disease cancer,
inflammation, neurodegenerative disease . Gary T. Wang and co-workers30 have
synthesized o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles (V) as

















         (IV)            (V)
J. J. Baldwin31-33 have prepared cyanopyridines exhibiting antihypertensive
activity. Streightoff34 and Seydal35 have studied the bacteriostatic effect of some
substituted 3-cyanopyridines. Francis and co-workers36 have studied the effect of some
substituted pyridines on the growth of the walker carcinosarcome-256 in tissue culture.
Barton et al.37 have reported fungicidal and insecticidal properties of cyanopyridines.
John A. Tucker et al.38 have synthesized novel piperazinyl oxazolidinone containing










                  (VI)
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Abdel Galil E. Amr and Mohamed M. Abdulla39 have synthesized fused
heterocyclic  pyridine derivatives (VII). Initially the acute toxicity of the compounds was
assayed via the determination of their LD50. These derivatives were found active as anti
inflammatory agents. Henryk Foks et al.40 investigated new 3-cyanopyridine derivatives









      (VII)
Hammana Abou and co-workers41 have studied anticancer and anti HIV activity
of 3-cyanopyridines. W. Von Behenburg and co-workers42 have synthesized 2-amino-
3,6-disubstituted pyridines as antiepileptic agents. V. Scott and E. Joseph43,44 have
prepared 2-amino-3-cyanopyridine derivatives which were found to be useful as
antipsoriasis pharmaceuticals. J. A. Vann Allan et al.45 have prepared fused heterocyclic
3-cyanopyridine (VIII). Abu and co-workers46 have prepared novel fused cyanopyridines













    (IX) (VIII)
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Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a valuable
therapy for diabetes. Edwin B. Villhauer and co-workers47 have reported the first use of
solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and a solution-
phase synthesis that is practical up to the multikilogram scale. One compound,
NVP-DPP728 (X), is profiled as a potent, selective and shortacting DPP-IV inhibitor
that has excellent oral bioavailability and potent antihyperglycemic activity.
In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesize some new cyanopyridines in search of agents possessing higher biological
activity with least side effect have been described as under.
SECTION-I  : S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F 4 -
   [2-(4-CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-







     NVP-DPP 728    (X)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-[2-(4-CHLOROPHENYL)
IMIDAZO[1,2-a]PYRIDIN-3-YL]-2-METHOXY-6-ARYLNICOTINONITRILES
Pyridine nucleus plays an important role in medicine, agriculture and
industrial chemistry.  In the light of these biological activities and variety of industrial
applications, some new  4-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-methoxy-
6-arylnicotinonitrile derivative of Type (III) have been prepared, by the cyclocondensation
of (2E)-3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones of
Type (I) with malononitrile in presence of sodium methoxide.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
biological activities of synthesized compounds were compared with standard drugs.
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2961 2975-2950 48
-CH3 C-H str. (sym.) 2868 2880-2860  ,,
C-H def. (asym.) 1447 1470-1435  ,,
C-H def. (sym.) 1384 1390-1370  ,,
Aromatic             C-H  str. 3054 3090-3030 49
C=C str. 1500 1540-1480  ,,
1077 1125-1090  ,,
1014 1070-1000  ,,
Pyridine C=C str. 1609 1650-1520 49
C=N str. 1455 1580-1550  ,,
Nitrile C=N str. 2322 2350-2120  ,,
Imidazo[1,2-a] C=N str. 1598 1612-1593  ,,
pyridine C-N str. 1094 1220-1020  ,,
Halide C-Cl str. 756 800-600 48
Ether C-O-C str. 1241 1260-1200  ,,
IR SPECTRAL STUDIES OF 4-[2-(4-CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-
YL]-2-METHOXY-6-(4-METHOXYPHENYL)NICOTINONITRILE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 4.17 3H singlet Ar-OCH3 -
2 6.91-6.95 1H dd Ar-H(f)         J=12.1, J=2.1
3 7.33-7.41 4H multiplet Ar-H(h,i,j,k)         -
4 7.49 1H singlet Ar-H(g) -
5 7.54-7.56 1H doublet Ar-H(e)         J=6.8, J=0.9
6 7.65-7.67 2H doublet Ar-H(a,a’)          J=7.8
7 7.75-7.77 2H doublet Ar-H(b,b’)          J=8.1




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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     EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-[2-(4-CHLOROPHENYL)
IMIDAZO[1,2-a]PYRIDIN-3-YL]-2-METHOXY-6-ARYLNICOTINONITRILES
[A] Synthesis of (2E)-3-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
arylprop-2-en-1-ones
See Part-I [A], Section-I [C].
[B] Synthesis of 4-[2-(4-Chlorophenyl)imidazo[1,2-a ]pyridin-3-yl]-2-
methoxy-6-(4-methoxyphenyl)nicotinonitrile
To a solution of (2E)-3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
(4-methoxyphenyl)prop-2-en-1-one (3.88 gm, 0.01 mol), malononitrile (0.60gm, 0.01
mol)  in methanol (10ml) and sodium methoxide, which prepared from sodium (46mg)
and absolute methanol (20ml) was added. The content was heated under reflux with
stirring for 12 hr. The reaction mixture was diluted with water and extracted with
chloroform. The excess solvent was distilled off and residue was crystallized from ethanol.
Yield 62%, m.p. 163oC, Anal. Calcd. for C27H19ClN4O2; Requires: C,69.45; H, 4.10;
N, 12.00; Found: C, 69.43 ; H, 4.08; N,11.99%.
Similarly,  other  4-[2-(4-chlorophenyl)imidazo[1,2-a ]pyridin-3-yl]-
2-methoxy-6-arylnicotinonitriles were prepared. The physical data are recorded in
Table No.3
[C] Biological evaluation of 4- [2- (4-Chlorophenyl)imidazo[1,2-a]pyridin-3-
yl]-2- methoxy-6-arylnicotinonitriles
Antimicrobial testing were carried out as described in Part-I [A], Section-1 [D].
The zones of inhabition of test solution are recorded in Graphical Chart No 3.
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INTRODUCTION
Mannich bases containing bridged N-atom exhibit pronounced biological
activities. The study of mannich reaction attracted a great deal of attention to the chemists
because it plays a vital role owing to their wide range of pharmacological and industrial
applications. Mannich bases are also employed as intermediate in chemical synthesis.1-3
Mannich base derivatives with bridge N-atom have been found to be potent drug
in medicinal science and possess wide range of biological activities like anticancer,
antibacterial, antimalarial, analgesic etc. Mannich bases have gained important because
of their technological applications in polymer chemistry4, especially as paints and surface
active agents and exhibits complexation characteristic with many transition metal ions.
Over the years there has been much contraversy about the mechanism of the
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SYNTHETIC ASPECT
Different methods have cited in literature to synthesize mannich bases by several
workers5,6 using various interesting substractes.
1. Yung-son Hon  et al.7 have prepared mannich base from the reaction of phenolic
compounds with a preheated mixture of dibromomethane and diethylamine.
2. Venkatesha Prabhu G. and Vanappayya D.8  have synthesized aminobenzylated
mannich bases by the condensation reaction between heterocyclic secondary
amines and benzaldehyde.
3. Pandeya and  Sriram D. Dave9  have  synthesized  mannich  bases  by  the
condensation of the acidic group of isatin with formaldehyde and secondary
amines.
4. Chi and co-workers10 have synthesized mannich base using 1,4,10,13-
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5. Seshaiah Krishnan et al.11 have synthesized mannich bases from the schiff bases
of isatin in presence of formaldehyde and diphenyl amine.
6. Christos A.  Kontogiorgis  et  al . 12 have synthesized mannich base of
coumarine.
THERAPEUTIC IMPORTANCE
Mannich bases are associated with a wide variety of biological activities and
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B. Shivarama Holla et al.26 have prepared mannich bases and tested them for
anthelmintic activity (I) and all the newly synthesized compounds (II) were tested for
their antibacterial and antifungal activity.
Amodiaquine27,28,a mannich base derivatives (III) which shown an antimalarial
activity superior than chloroquine in areas of high  chloroquine resistance. M. L. Edwards
et al.29 have prepared the mannich base of  4-phenyl-3-buten-2-one as an antiherps
agent. Malcolm K. Scott and co-workers30 have prepared the pyrrole mannich base
(IV) as a potent antipsychotic agents.
J. Knoll et al.31 have prepared the mannich base (V) which was the most potent
neuroleptic compound of a series of aryl substituted analogues. Molindone (VI) which
has been reported to demostrate potent neuroleptic activity32. Jan Balzarini and


































         (III)       (IV)
(I)                   (II)
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Gul H. I. et al.34,35 have documented antifungal activity of bis mannich bases
derived from acetophenones and some mono mannich bases evaluated for their
anticonvulsant activity. Shingare M. S. et al.36 have described the synthesis and the
antiviral activity of mannich bases (VII).
Movrin M. and Maysinger D.37 have synthesized mannich bases from nitroxoline
and reported them as biologically active agents. Ojanen T. and coworkers38 have reported
antifungal activity of some mono, bis and quaternary mannich bases derived from
acetophenone. Li Y., Yang Z. S. et al.39 have synthesized some mannich base derivatives
and reported their antimalarial activity.
Lorand T. and Kocsis B.40 have synthesized some new mannich ketones and
reported their antibacterial activity. Erol D. D., Rosen A. et al.41 have synthesized






















                (VII)
R= H,4-Me, 5-OMe, 5-Cl, 6-Br
     (V)              (VI)
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2(3H)-benzoxazolones and reported their biological activities. H. M. Hassan42 have
synthesized some new mannich bases containing 1,8-napthyridine moiety and reported
their antimicrobial activity.
H. S. Joshi et al.43 have been synthesized some new amino benzylated mannich
bases and reported  their antimicrobial activities.
In view of the importance of mannich bases as versatile synthetic intermediates
and the availability of scanty literature on therapeutic properties, we have undertaken
the preparation of mannich bases in following sections.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF N-{[2-(4 -
 C H L O R O P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ]
 METHYL}-N,N-DIALKYL/ARYLAMINES
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SECTION-I
SYNTHESIS AND BIOLOGICAL EVALUATION OF N - { [ 2 - ( 4 -
CHLOROPHENYL)IMIDAZO[1,2-a ]PYRIDIN-3-YL]METHYL}-N ,N-
DIALKYL/ARYLAMINES
In view of getting better therapeutic agent and considering the association of
various biological activity with imidazo[1,2-a]pyridine nuclei, the preparation of mannich
bases of Type (IV) have been undertaken from 2-(4-chlorophenyl)imidazo[1,2-a]pyridine
with primary/secondary amines and formaldehyde in methanol.
The constitution of newly synthesized compounds have been supported by using
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activity of the synthesized compounds have been compared with standard
drugs.
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IR SPECTRAL STUDIES OF  2-(4-CHLOROPHENYL)-3-(MORPHOLIN-4-
YLMETHYL)IMIDAZO[1,2-a]PYRIDINE
 Observed
Alkane C-H str. (asym.) 2966 2975-2950 44
-CH3 C-H str. (sym.) 2851 2880-2860  ,,
C-H i.p.def. (asym.) 1411 1470-1435  ,,
C-H o.o.p. def. 1361 1390-1370  ,,
Aromatic C-H  str. 3060 3090-3030 45
C=C str. 1530 1540-1480  ,,
C-H i.p.def. 1046 1125-1000  ,,
C-H o.o.p. (def) 838 835-810  ,,
CH2 str. 1423 1500-1350  ,,
Imidazo[1,2-a] C=N str. 1597 1650-1580 44
pyridine C-N str. 1206 1220-1020  ,,
C=C str. 1488 1540-1480  ,,
Ether C-O-C str. 1242 1260-1200  ,,
Halide C-Cl str. 779 800-600  ,,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range :
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1 1.64-1.67 2H triplet Ar-H (d,d’)      -
2 3.27-3.31 2H triplet Ar-H (c,c’)      -
3 3.53 1H singlet -CH2 (e)      -
4 6.78-6.81 1H dd Ar-H (f)          J=9.1, J=2.8
5 7.170-7.193 1H dd Ar-H (g)          J=6.8, J=2.2
6 7.39-7.42 1H dd Ar-H (h)          J=9.5, J=1.8
7 7.622-7.644 2H doublet Ar-H (a,a’)    J=6.7
8 7.87-7.90 1H dd Ar-H (i)           J=9.8, J=2.5




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-(MORPHOLIN-4-
YLMETHYL)IMIDAZO[1,2-a]PYRIDINE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF N - { [ 2 - ( 4 -
CHLOROPHENYL)IMIDAZO[1,2-a ]PYRIDIN-3-YL]METHYL}-N ,N-
DIALKYL/ARYLAMINES
[A]   Preparation of 2-(4-Chlorophenyl)imidazo[1,2-a]pyridine
         See Part-I [A], Section-I [A]
[B] Preparation of 2-(4-Chlorophenyl)-3-(morpholin-4-ylmethyl)imidazo[1,2-
a]pyridine
A mixture of  2-(4-chlorophenyl)imidazo[1,2-a]pyridine (2.88 gm, 0.01 mol),
formaldehyde (0.3 gm, 0.01 mol) and morpholin (0.87 gm, 0.01 mol) in methanol (50
ml) was stirred for 8 hrs. and left overnight in a freeze. The solution was poured onto
crushed ice. The product was isolated, dried and recrystallised from hexane Yield 60%,
m.p. 142oC. Anal. Calcd. For C18H18ClN3O : C, 65.95; H, 5.53; N, 12.82 %; Found: C,
65.94; H, 5.52; N, 12.81 %.
Similarly other amines condensed with 2-(4-chlorophenyl)imidazo[1,2-a]pyridine.
The physical constants are recorded in Table No.4.
[C] Biological evaluation of N-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methyl}-N,N-dialkyl/arylamines
Antimicrobial testing was carried out as described in Part-I [A], Section-I [D].
The zones of inhibition of compounds are recorded in Graphical Chart No.4.
Studies on Chemical Entities....
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 INTRODUCTION
Isoxazole is a five membered heterocyclic compound having two hetero atoms:
oxygen at position 1 and nitrogen at position 2. Claisen first reported an isoxazole (I)
for a product from the reaction of 1,3 diketone with hydroxylamine.1 Subsequently a
solid foundation for the chemistry of isoxazole was laid down by Claisen and his students.
It was shown to possess typical properties of an aromatic system but under certain
reaction conditions. Particularly in reducing or basic media, it becomes very highly labile.
The next important contribution to the chemistry of isoxazoles was made by
Quelico2 in 1945, when he begane to study the formation of isoxazoles from nitrile
N-oxide and unsaturated compounds.
SYNTHETIC ASPECT
Isoxazoles can be prepared by various methods, some of  them are described as under.
1. Crawley L. S. and Fan Shawe W. J.3 have prepared isoxazole (II) from α,β-
unsaturated carbonyl compounds, hydroxyl amine hydrochloride and KOH in methanol.
2. Tayade V. B. et al.4 have synthesized some new 3,5-diarylisoxazoles from the
reaction of 2-aryl acetophenones with hydroxyl amine hydrochloride in presence
of alkali.
3. Dawood Kamal et al.5 have prepared isoxazole derivatives from enamino nitriles.
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achieved in good yields in a rapid and simple way by using N-acetoacetyl
derivatives.
5. A variety of 3,5-disubstituted 4-bromoisoxazoles7  (IV) are readily prepared
in good to excellent yields under mild reaction conditions.
6. Keisuke Suzuki et al.8 have synthesized functionalized isoxazole derivatives (V)
by cyclocondensation of C-chlorooximes with cyclic 1,3-diketones.
7. Solid phase synthesis of isoxazole derivatives based on aminoacids was
repor ted  by Lidia  De Luca and co-workers9 in  the  presence  of  bas ic
catalyst  and dichloromethane used as a solvent . One pot  synthesis  of
polyfunctionalized isoxazoles 10 have been synthesized by the reaction of
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Julia Kaffy et al.36 have been synthesized various five membered heterocycles
with oxygen and nitrogen atoms. The 4,5-diarylisoxazole (VI) exhibited greater antitubulin
activity, but modest antiproliferative activity. Kai Fan Cheng 37 have been synthesized
3-(4-hydroxyphenyl)-4,5-dihydro-5-aceticacidmethylester isoxazole, an inhibitor of the
proinflammatory cytokine MIF, two critical modifications and chiral resolution have
significantly improved the potency of the inhibition.Compound (VII) inhibits MIF
tautomerase with an IC50 of 550 nM.
Welsing P. M. et al.38 have documented the isoxazoles as tumor necrosis
factorblocking agents and leflunomide for treating rheumatoid arthritis in the
Netherlands. Bingham S. J. et al.39 have synthesized isoxazole derivatives as an
antiulcer agents. Barbachyn M. R. et al.40 have described the phenylisoxazolines as novel
and viable antibacterial agents active against Gram-positive pathogens. Masui et al.41
have prepared isoxazoles having pesticidal activity. Some isoxazoles gave excellent
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Aicher Thomas D. et al.43 reported isoxazoles  (VIII) as hypoglycemic agents.
H. S. Joshi et al.44 have synthesized isoxazole derivatives (IX) and reported their
antitubercular and antimicrobial activity.
Stefano Chimichi and co-workers45 have investigated cytotoxic activity of 3-
quinolinoyl isoxazoles (X) against leukemia and adenocarcinoma derived cell lines in
comparison to the normal human keratinocytes. Novel cyclohexyl drug resistance modulators46
(XI) were synthesized and evaluated for in vitro inhibition of the drug resistance transporter,
MRP1.
Moreover, S. Rung and D. Dus47 have synthesized some new isoxazoles as
remedy for leukemia. M. Scobie and co-workers48 have prepared isoxazole
derivatives and studied their antitumor activity. G. Daidone et al.49 synthesized 3-(isoxazol-
3-yl)-quinazolin-4-(3H)-one derivative and tested for their analgesic and
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effect. Salter M. W. et al.50 have prepared some isoxazole as cellular neuroplasticity
mechanisms mediating pain persistence. Matringe M. et al.51 have reported some new
p-hydroxyphenylpyruvate dioxygenase inhibitor resistant plants. Mehlisch D. R. et al.52
have synthesized isoxazole derivative as analgesic efficacy of intramuscular parecoxib
sodium in postoperative dental pain. Ray W. A. et al.53 have reported isoxazole
derivative as cardiovascular toxicity of valdecoxib.
With an intension of preparing the compounds possessing better therapeutic
activity, we have under taken the preparation of isoxazoles bearing imidazo[1,2-a]pyridine
nucleus which have been described as follows.
SECTION I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-(4-
 CHLOROPHENYL)-3-(3-ARYLISOXAZOL-5-YL)IMIDAZO[1,2-
 a]PYRIDINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-(4-CHLOROPHENYL)
-3-(3-ARYLISOXAZOL-5-YL)IMIDAZO[1,2-a]PYRIDINES
Isoxazole derivatives have attracted considerable attention due to their
potential biodynamic behaviour. In view of these valid observations, the synthesis
of  some new isoxazoles of Type (V) have been undertaken by the reaction of chalcones
of Type (I) with hydroxylamine hydrochloride in presence of sodium acetate in glacial
acetic acid.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Aromatic C-H  str. 3049 3090-3030 54
C=C str. 1543 1540-1480  ,,
C-H i.p. def 1094 1125-1000  ,,
C-H o.o.p 812 835-810  ,,
C-O str. 1042 1070-1000  ,,
Imidazo[1,2-a] C=N str. 1598 1612-1593 55
pyridine C-N str. 1045 1220-1020  ,,
C=C str. 1517 1680-1550  ,,
Isoxazole C=C str. 1655 1680-1550  ,,
C=N str. 1543 1690-1460  ,,
N-O str. 827 850-810  ,,
Halide C-Cl str. 799 800-600 54
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:







































IR SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-[3- (4-
CHLOROPHENYL)ISOXAZOL-5-YL]IMIDAZO[1,2-a]PYRIDINE
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.45 3H singlet Ar-CH3     -
2 6.84 1H singlet Ar-H(c)     -
3 7.13-7.15 2H doublet Ar-H(f,f’) J=6.2
4 7.45-7.54 4H multiplet Ar-H(g,h,i,j)     -
5 7.68-7.71 2H doublet Ar-H(d,d’) J=8.8
6 7.77-7.80 2H doublet Ar-H(b,b’) J=8.4




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-(4-CHLOROPHENYL)
-3-(3-ARYLISOXAZOL-5-YL)IMIDAZO[1,2-a]PYRIDINES
[A] Synthesis of (2E)-3-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
arylprop-2-en-1-ones
See Part-I [A], Section-I [C].
[B] Synthesis of 2-(4-Chlorophenyl)-3-[3-(4-chlorophenyl)isoxazol-5-yl]
imidazo[1,2-a]pyridine
To a solution of (2E)-3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
(4-chlorophenyl)prop-2-en-1-one (3.93 gm, 0.01 mol) in ethanol (25 ml), anhydrous
sodium acetate (0.739 gm, 0.01 mol) and hydroxylamine hydrochloride (0.59 gm, 0.01
mol) in acetic acid were added. The reaction mixture was refluxed on oil bath for 12 hr.
The product  was isolated and crystallized from ethanol. Yield 56 %, m.p. 130oC Anal.
Calcd. For C22H13Cl2N3O Requires ; C, 65.04; H, 3.23; N, 10.34; Found C, 64.10, H,
3.22; N, 10.33 %.
Similarly, other 2-(4-chlorophenyl)-3-(3-arylisoxazol-5-yl)imidazo[1,2-
a]pyridines were prepared. The physical data are recorded in Table No.5.
[C] Biological  evaluation of  2-(4-Chlorophenyl)-3-(3-aryl isoxazol-5-
yl)imidazo[1,2-a]pyridines
Antimicrobial testing were carried out as described in Part-I [A], Section-1 [D].
The zones of inhibition of test solution are reported in Graphical Chart No 5.
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 INTRODUCTION
Oxopyrimidine and its derivatives represent one of the most active class of
compounds possessing a wide spectrum of biological activities. Pyrimidine derivatives
which occurs in natural products like nucleic acid, vitamin-B and having remarkable
pharmaceutical importance because of their broad spectrum of  biological activities. Several
analogs of nucleic acids like fluorouracil which has been used in cancer treatment.
Pyrimidines are among those molecules that make life possible as being some of the building
blocks of DNA and RNA.
Some oxo pyrimidines of  physiologically as well as therapeutically  importance
are as under : e.g., Blasticidin (I), Zidovudine
SYNTHETIC ASPECT
Different methods for the synthesis of pyrimidinones have been cited in the
literature.1
1. Biginelli2 investigated that condensation of aromatic aldehyde with β-ketoester
and urea yield the pyrimidine derivatives (II).
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2. Oliver Kappe et al.3 have synthesized dihydropyrimidine-5-carboxylicacid (III)
in two steps by multicomponent condensation of benzyl or allyl β-ketoesters with
aldehyde and urea, followed by suitable benzyl or allyl deprotection strategies.
         (III)
3. There are many other methods of pyrimidine ring synthesis which are of more
limited scope. The reaction of 1,3-dicarbonyl compound or an equivalent
reagent with formamide provides a route of several pyrimidine which are
unsubstituted at the 2-position.
4. An efficient and robust solid-phase synthesis of 6-substituted-2,5,6,8-tetrahydro-
3H-imidazo[1,2-a]pyrimidin-7-ones (IV), 3-substituted-1,3,4,6,7,8-hexahydro-
pyrimido[1,2-a]pyrimidin-2-ones (V) using Baylis Hillman reagent.4
5. The condensation of the azaenolates derived from readily available ketimines























(IV)                                         (V)
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fluorinated 1,3-vinylogous amides. These versatile compounds in turn react
with triphosgene to yield new fluorinated pyrimidin-2(1H)-ones (VI) in high
yields5.
6. Fikret karci et al.6 have synthesized 4-amino-1H-benzo[4,5]imidazo[1,2-a]
pyrimidin-2-one by the reaction of 2-aminobenzimidazole with ethylcyanoacetate.
REACTION MECHANISM
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THERAPEUTIC IMPORTANCE
It is revealed from the literature survey that pyrimidine derivatives have been











Swaminathan R. et al.29 have synthesized P38 MAP Kinase inhibitors based on














  (VII)   (VIII)
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Sanjay Batra et al.30 have synthesized several 1-(2-cyano-3-aryl-allyl)-3-urea
by the reaction between allylamines generated from Baylis-Hilman acetates and
substituted isocyanates and isothiocyanate. Further, their cyclization in the presence of
a base led to the formation of 5-arylmethyl-4-imino-3-aryl-3,4-dihydro-1H-pyrimidin-
2-ones (IX) and were tested for their antibacterial activity.
             (IX)
2-(Arylcarbonylmethyl) thio-6-alpha-naphthylmethyl  derivat ives of
dihydroalkoxybenzyloxopyrimidines31 (DABO) were newly found to exhibit activity
against both HIV-1 and HIV-2. These compounds were evaluated for their in vitro
anti-HIV activity in MT-4 cells. The IC(50) values for anti-HIV-1 and HIV-2 were
found moderately active.
(±)-1-(anti-3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-
dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one (RO4383596) is a potent and selective
inhibitor of the pro-angiogenic receptor tyrosine kinases KDR, FGFR, and PDGFR32.
This agent has an excellent pharmacokinetic profile and is highly efficacious in rodent
models of angiogenesis upon oral administration.
Relationship between the topological indices and anti-HIV activity of
dihydro(alkylthio)(napthylmethyl) oxopyrimidines (5-DABO) has been investigated by
Lather V. and Madau A. K.33  The use of models based upon these topological indices
resulted in prediction of anti-HIV activity with an accuracy ranging from 86% to 89%.
Herve Ganeste and co-workers34 synthesized substituted 1H-pyrimidin-2-one  (X) with
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2-Alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-
4(3H)-ones (F (2)-NH-DABOs) 4,5 belonging to dihydro-alkoxy-benzyl-oxopyrimidine
(DABO)35 and bearing different alkyl and arylamino side chains at the C (2)-position of
the pyrimidine ring were designed as active against wild type (wt) Human Immunodeficiency
virus type 1 (HIV-1) and some relevant HIV-1 mutants.
Thirty six allyl substituted oxopyrimidine analogues36 such as barbituric acid (BA),
barbiturates, uracil, thymine, and related derivatives including 13 new compounds were
synthesized and their pharmacologic effects ([hypnotic activity, anticonvulsant activity
against pentylentetrazol (PTZ)-induced seizures, and LD(50)]) and interactions with the
barbiturates were evaluated in mice and rats.
Cano Soldado P. et al.37 have described pyrimidine derivatives as nucleoside
inhibitors of HIV-1. Gompel M. et al.38 have reported new family of protein kinase
inhibitors isolated from the ascidian aplidium meridianum. Junmei Wang et al.39 have
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Bruce M. A. and co-workers40 have prepared the dihydropyrimidinones (XII)
as NPY antagonists. Sidler and Larsen41 have reported pyrimidinone derivatives
(XIII), useful as an α-adrenergic receptor antagonists.
Pyrimidinone derivatives42,43 (XIV) have been found to be calcium channel blocker.
Barbuliene M. M. et al.44 have synthesized pyrimidinones as antiinflammatory agent.
Amuti Kofies et al.45 have suggested pyrimidinones (XV) and (XVI) as
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Thus, diverse biological activities have been encountered in compounds
containing oxopyrimidine ring system. To further assess the potential of such type of
compounds, study of oxopyrimidines have been carried out as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-[2-(4-
 CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYL
 PYRIMIDIN-2(1H)-ONES
Studies on Chemical Entities....
                                Oxopyrimidines...
123
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 - [ 2 - ( 4 -
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-
2(1H)-ONES
In the past years considerable evidence has been accumulated to demonstrate
the efficiency of pyrimidinones. 6-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-
4-arylpyrimidin-2(1H)-ones of  Type (VI) have been prepared by the condensation of
(2E)-3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones of
Type (I) with urea in presence of  basic catalyst as shown under.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
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IR SPECTRAL STUDIES OF 6-[2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]-4-(2,4-DICHLOROPHENYL)PYRIMIDIN-2(1H)-ONE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:









Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Aromatic C-H  str. 3075 3090-3030 46
C=C str. 1464 1540-1480  ,,
1094 1125-1090  ,,
1013 1070-1000  ,,
Halide C-Cl str. 785 800-600 47
Vinyl CH=CH str. 3015 3050-3000 46
oxopyri. C=O str. 1658 1672-1652  ,,
imidazo[1,2-a] C=N str. 1591 1612-1593 47
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 6.22 1H singlet Ar-H (h)    -
2 7.12-7.16 2H quartet Ar-H (a,a’) J=12.2
3 7.38-7.41 2H doublet Ar-H (b,b’) J=9.6
4 7.46-7.53 4H multiplet Ar-H(d,e,f,g)    -
5 7.54-7.56 1H doublet Ar-H (i) J=7.1
6 7.64 1H singlet Ar-NH (c)    -
7 7.77-7.80 1H doublet Ar-H (j) J=9.7




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 6 - [ 2 - ( 4 -
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-
2(1H)-ONES
[A] Synthesis of (2E)-3-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
arylprop-2-en-1-ones
See Part-I [A], Section-I [C] .
[B] Synthesis of 6-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-4-
arylpyrimidin-2(1H)-one
A mixture of (2E)-3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-(4-
chlorophenyl)prop-2-en-1-one (3.93 gm, 0.01 mol) and urea (0.77 gm, 0.01 mol) in
ethanol (20 ml) was refluxed on waterbath  in presence of alcoholic KOH for 8 hr. The
excess solvent was distilled off and the residue was neutralized with 20 % HCl, the
separated solid was filtered out and crystallized from methanol. Yield 34 %, m.p. 195oC
Anal. Calcd. for C23H14Cl2N4O Requires: C, 59.04; H, 2.80; N, 12.93 % Found: C,
59.02; H, 2.81, N, 12.90 %.
Similarly, other 6-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-4-arylpyrimidin-
2(1H)-ones were prepared. The physical data are recorded in Table No. 6.
[C] Biological evaluation of 6-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-
yl]-4-arylpyrimidin-2(1H)-ones
Antimicrobial testing were carried out as described in Part-I [A], Section-I [D].
The zones of inhibition of test solution are reported in Graphical Chart No. 6.
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INTRODUCTION
Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are also
known as Schiff’s base and they are well known interemediate for the preparation of
azetidinone, thiazolidinone, formazone, arylacetamide and many other derivatives.
These are the compounds contain characteristic -C=N group.
Azomethines are obtained mainly by warming the aldehyde and aromatic amine
togethar. However, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is complited by trace of acid
in other cases the hydrochloride of the amines can be used in the synthesis.
In general Schiff’s bases do not react further with either of the reagents used in
their preparation as do most of the other types of simple intermediates.
SYNTHETIC ASPECT
1. General account of the summary of reaction of aldehydes with amine
(aromatic or aliphatic) has been reviewed by Murray.1
                      R-CHO R'-NH2 R-CH=N-R'+
2. Strache2 and Van Alphen3 have prepared imine involves in two steps.
(a)  Addition of the amine to the carbonyl group of the aldehyde gives aldol.
      The aldol is rarely capable of isolation.
            R-CHO R'-NH2+ R-CHOHNHR'
(b)  The loss of water to give an imine (azomethine), this corresponds to
      the “crotonaldehyde stage” of the aldol condensation.
            
R-CH=N-R'R-CHOHNHR' + H2O
3. Oddo and Tognacchini4 have introduced the comparative rates of formation
of Schiff ’s base from aniline, substituted aniline and aromatic aldehyde
using a cryscopic method follow the course of reaction.
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4. Amanda J. Gallant et al.5 have prepared schiff bases by the condensa tion of
equimolar quantity of 3,6 diformyl catechol and substituted o-phenylenediamine.
5. Pierre L. Beaulieu and co-workers6 have synthesized (E)-N-phenylmethylene
glycineethyl ester by the cyclocondensation of glycine ethylesterhydrochloride,
t-butylmethyl ether (TBME) and benzaldehyde followed by anhydrous
Na2SO4 and triethylamine.
THERAPEUTIC IMPORTANCE
Schiff bases exhibit a wide range of pharmacological activities like antifungual,
antibacterial, antiviral, antiinflammatory etc. Pandey Taruna et al.7 prepared azomethines
and their boron complexes and screened for their antifungal  and antibacterial properties.
It is evident that azomethines alone were quite toxic but their activity increased after
complexation. Omar et al.8 have determined cyclocondensation of azomethines  having
good antischistosomal activity. Praveen M. and co-workers9 have synthesized a novel
class of acetyl ferrocene derived from Schiff bases having antimicrobial activity.
Mehta R. H. et al.10 have synthesized coummarin schiff’s base derivatives of (I)
and examined for their antibacterial activity. Khalafallah A. K. and Hassan M. E.11 have


















Na2SO4 TBME 48 hrs
N COOEt
HCl.
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antifungal activity. Sharaf El-Din, and Nabaweyal12 have synthesized some azomethine
derivatives (II) having good antibacterial activity.
Chohan et al.13 have synthesized azomethines, which have been  screened and
compared for their antibacterial action against bacterial  species Escherichia coli,
Pesudomonus aeruginoase and Klebisella  pneumoniase. Das Joydip14 have synthesized
trans-N-refinylidene-n-butylamine (III) which found stabillized in liposomes of
phophatidylcholine. The rate of formation of the Schiff’s base is found to decrease with
increasing cholesteral concentration in the membrane. Patel V. M.15 have synthesized
some new  Schiff’s bases having good antibacterial activity.
Deshmukh M. D. and Doshi A. G.16 prepared some new  Schiff’s bases show
good antimicrobial activity against test organism S. aureus, E. coli, Saigella dysenteridse
and Salmonella typhi. Wang and Yangang17 have synthesize diazomethines having  plant
hormone activity. Das Arima et al.18 have prepared Schiff’s bases of  aminohydroxy
guanidine (SB-AHG5) and tested  for antiviral  activity against Herpes Simplex virus
(HSV-1) and adenovirus (Ad-5) along with 11 other heterocyclic SB-AHG5.
Pawar R. P. et al.19 have synthesized azomethines by the condensation of
iodovanillin with different substituted aromatic amines and tested for antibacterial activity.
Ergenc  and co-workers 20 have  synthes ised  azomethine  der iva t ives
having antifungal activity. Yadav Bodke21 have synthesized some azomethines and tested
R  =   Ph, 4-Br-C6H4, 4-NO2-C6H4,
          2-Cl-C6H4CONH











   (III)
        3,4-(OMe)2
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for their biological activity. B. Shivarama Holla et al.22 have prepared and reported
anticancer activity of some new Schiff bases.
Cascaval Alexandru et al.23 have synthesized azomethines, which have good
analgesic and antipyretic properties. Pandeya S. N. et al.24 have synthesized Schiff  bases
showed good activity against Vibrio cholerae non-o., Shigella boydii, Enterococcus
faecalis and Edwaredsiella torla with MIC in the rang of 10-25 µg/ml. Some compounds
were found to be active against Salmonellal typhi  and Vibro cholerae-0 ,
(MIC 25-150 µg/ml).
Ali Yousif et al.25 have synthesized some Schiff’s base derivatives of glucose
containing acetylenic bond and tested for their bactericidal activity against E. coli and
Staphylococcus aureus.
Ravindra V. Chambhare et al.26 have prepared some azomethines and tested for
their antimicrobial activity. B. Shivarama Holla et. al.27 have synthesized azomethines of
(IV) having antibacterial and anti-inflammatory activity.
Ram Tilak et al.28 have synthesized some Schiff’s bases, thiazolidinones 4-
triazolines, and formazones of 2-chloro phenothiazines and screened against carrageenin-
induced edema in albino rats. The thiazolidinones showed promising antiinflammatory
activity.
Looking to the interesting properties of azomethines, we have synthesized some
new azomethines, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION  OF N-{(1E)-[2-(4-
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}
-N-ARYLAMINES
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF N-{[2-(4-
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-
N-ARYLAMINES
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SECTION-I
S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F N - { ( 1 E ) - [ 2 - ( 4 -
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-N-
ARYLAMINES
Looking to the interesting properties of azomethines, with an intension to
synthesising better therapeutic agents, azomethine derivatives of Type (VII) have been
synthesized by the condensation of 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde with different aromatic amines in order to study their biodynamic behavior.
The constitution of the synthesized products have been characterised by using
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The biological
activities of the synthesised compounds were compared with standard drugs.
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2958 2975-2950  29
-CH3 C-H str. (sym.) 2872 2880-2860   ,,
C-H def. (asym.) 1470 1470-1435   ,,
C-H def. (sym.) 1385 1390-1370   ,,
Aromatic C-H  str. 3051 3090-3030  30
C=C str. 1496 1540-1480   ,,
C-H i.p. def. 1089 1125-1000   ,,
C-H o.o.p. def. 817 835-810   ,,
Schiff base C=N str. 1613 1660-1580  29
Imidazo[1,2-a] C=N str. 1584 1612-1593  30
pyridine C-N str. 1215 1220-1020   ,,
Halide C-Cl str. 762 800-600   ,,
IR SPECTRAL STUDIES OF N-{(1E)-[2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]METHYLENE}-N-(4-METHYL PHENYL)AMINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
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    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF  N-{(1E)-[2-(4-CHLOROPHENYL) IMIDAZO[1,2-
a]PYRIDIN-3-YL]METHYLENE}-N-(4-METHYLPHENYL)AMINE
       1 2.40          3H      singlet Ar-CH3                     -
       2 7.06-7.08          2H      doublet Ar-CH (a,a’)           J=6.2
       3 7.28          1H      singlet Ar-CH (g)           -
       4 7.09-7.32          4H      multiplet Ar-CH (c,d,e,f)          -
       5 7.46-7.51          1H      multiplet Ar-CH (i,i’)           -
       6 7.73-7.75          2H      doublet Ar-CH (b,b’)           J=6.8
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF N -{ (1E ) - [2- (4-
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-N-
ARYLAMINES
[A] Synthesis of 2-(4-Chlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde
See, Part-I [A], Section-I [B].
[B] Synthesis of  N-{(1E)-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-N-(4-methylphenyl)amine
A mixture of 2-(4-chlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde (2.28
gm, 0.01 mol) and p-toludine (1.08 gm, 0.01 mol) in methanol (20 ml) in presence of
catalytic amount of  glacial acetic acid was refluxed for 6 hr. The contents were cooled
and product isolated was crystallized from methanol. Yield, 52%, m.p. 188oC, C21H16ClN3
; Found : C, 72.93%; H, 4.66%; N,12.15%; Requires : C, 72.92%; H, 4.65%; N,
12.14%.
Similarly, other N-{(1E)-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methylene}-N-
arylamines were prepared. The physical constants are recorded in Table No. 7.
[D] Biological evaluation of   N-{(1E)-[2-(4-Chlorophenyl)imidazo[1,2-
  a]pyridin-3-yl]methylene}-N-arylamines
 Antimicrobial testing was carried out as described in Part-I [A], Section-I [D].
The zone of inhibition of the test solution are recorded in Graphical Chart No. 7.
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SECTION-II
SYNTHESIS AND BIOLOGICAL EVALUATION OF N - { [2 - (4 -
C H L O R O P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] M E T H Y L } -N -
ARYLAMINES
Aminomethyl derivatives of heterocyclic compounds are associated with diverse
therapeutical activities. These finding prompted us to synthesize some representative
aminomethyl derivative of Type (VIII) bearing imidazo[1,2-a]pyridine moiety obtained
by  selective reduction of (imine group) Schiff’s bases of  Type (VII) with  sodium
borohydride in controlled experimental condition as shown in the reaction  scheme.
Type (VII)
The constitution of the synthesized products have been characterised by using
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The biological
activities of the synthesised compounds were compared with standard drugs.
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2963 2975-2950 29
-CH3 C-H str. (sym.) 2852 2880-2860   ,,
C-H def. (asym.) 1439 1470-1435   ,,
C-H def. (sym.) 1379 1390-1370   ,,
CH2 str. 1470 1500-1350   ,,
Aromatic C-H  str. 3055 3090-3030 30
C=C str. 1498 1540-1480   ,,
C-H i.p. def. 1088 1125-1090   ,,
Halide C-Cl str. 761 800-600 29
Imidazo[1,2-a] C=N str. 1598 1612-1593 30
pyridine C-N str. 1219 1220-1020   ,,
Amine N-H str. 3338 3400-3200   ,,
IR SPECTRAL STUDIES OF N-{[2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]METHYL}-N-(4-METHYLPHENYL)AMINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
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    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF N-{[2-(4-CHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]METHYL}-N-(4-METHYLPHENYL)AMINE
       1 2.40          3H     singlet  Ar-CH3                    -
       2 4.75          2H     singlet  -CH2 (g)           -
       3 7.06-7.09          2H     multiplet  Ar-CH (j,j’)
       4 7.149-7.174          2H     doublet  Ar-CH (i,i’)        J=7.5
       5 7.219-7.231          2H     doublet  Ar-CH (a,a’)          J=6.7
       6 7.45-7.51          4H     multiplet         Ar-CH (c,d,e,f,)       -
       7 7.73-7.76          2H     doublet  Ar-CH (b,b’)          J=9.2
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF N - { [2 - (4 -
C H L O R O P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] M E T H Y L } - N -
ARYLAMINES
[A] Synthesis of  N-{(1E)-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-
3-yl]methylene}-N-(4-methylphenyl)amine
See, Part-VI [A], Section-I [B].
[B] Synthesis  of  N-{[2-(4-Chlorophenyl) imidazo[1,2-a]pyridin-3-yl]
  methyl}-N-(4-methylphenyl)amine
 Sodium borohydride (0.15 mol, 0.57gm) was added to a methanolic
solution of N-{(1E)-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methylene}-N-(4-
methylphenyl)amine (0.01 mol, 3.45 gm) over a period of  30 minutes at
temperature 5-10oC with constant stirring. The reaction mixture  was kept over night at
room temp. The excess borohydride was neutralized by adding water and the product
was extracted with ether. The ether extract was washed with water untill become
neutral, then dried over anhydrous Na2SO4 and finally  the ether  was evaportated  to
give aminomethyl derivatives.  Yield, 63%, m.p. 157oC, C21H18ClN3; Found : C, 72.51;
H, 5.52; N, 12.08 %; Requires : C, 72.50; H, 5.51; N, 12.02 %.
Similarly, other N-{[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl] methyl}-N-
arylamines were prepared. The physical constants are recorded in Table No. 8.
[C] Biological evaluation of N-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-
3-yl]methyl}-N- arylamines
Antimicrobial testing was carried out as described in Part-I [A], Section-I [D]. The
zone of inhibition of the test solution are recorded in Graphical Chart No. 8.
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INTRODUCTION
The discovery of the 2-substituted-5-imidazolines dates back to the year 1888,
when A. W. Hoffman1 for the first time discovered 5-oxo-imidazoline by heating N’-
diacetylethylene diamine in a stream of dry hydrogen chloride. Imidazolinone is a five
membered heterocycle having 2-nitrogen atoms at 1 and 3 positions and C=O group at

























(I)       (II)          (III)
Moreover, some compounds were prepared by A. Ladenburg2 by the fusion of
two equivalents of sodium acetate with one equivalent of ethylene diamine dihydrochloride.
SYNTHETIC ASPECT
Various methods have been reported for the synthesis of imidazolinones in
literature.3 Aminolysis4  of oxazolone with amine leads to the formation of imidazolinones
which has been reported in literature.
1. A. Saxena et al.5 have synthesized new imidazolinones as under.
2. Hisato Takeuchi et al.6 have synthesized imidazolinones by the reaction of
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3. Jean Michel Lerestif et al.7 have synthesized imidazolinone from α-aminoester.
4. Allimony et al.8 have synthesized new imidazolinone derivatives by
conventional method.
5. Feng-Jun-Cai  et  al . 9 have reported 5-imidazolinone derivat ives by
microwaves irradiation.
MECHANISM
Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylamino acryclic acids obtained from the
condensation of azalactone and primary amines can be converted into imidazolinones as
shown in equation (IV). The ring formation can be affected under a variety of conditions.
































R’-NH2, DryC5H5N/Abs. C2H6OH, K2CO3
(a) (b)    (c)
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THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and tolazoline
and phenotolamine as adrenergic blocking agents. Various imidazolinones are known to














14. Sedative and hypnotics30
15. Potent CNS depressant31,32
16. Hypertensive33
17. Thrombin inhibitor34
K. K. Awasthi et al.35 have synthesized some new imidazolinone derivatives (V)
and reported their antimicrobial activity. A. J. Baxi and co-workers36 have synthesized
several imidazolinone derivatives by the condensation of some known sulpha drugs with
5-oxazolone derivatives, products have been screened for their in vitro growth
inhibitory activity against several microorganisms and  in vivo anticonvulsant activity.
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    (V)
Moreover Yoneda Naoto et al.37 have synthesized imidazolinones as
antihypertensive agent. R. C. Dage et al.38 have documented cardiotonic imidazolones.
Rossello et al.39 have prepared imidazolones as antifungal agent. Cooper A. B. and
co-workers40 have found that imidazolones are inhibitors of farnesyl proteing
transferase. Machii Daisuke et al.41 have synthesized new imidazolones as a
telomeres inhibitors and antitumor agents. Jean M. R. et al.42 have synthesized
imidazolones and tested as antileishmanial agent. Chafiq Hamdouchi et al.43 have
reported imidazolinones and screened for their potent and broad spectrum activity.
Xu Zhi-Feng et al.44 have synthesized imidazolinones as biological agent. Geoffrey
et al.45 and Pilkington et al.46 have described and studied antifungal activity of
imidazolinones. L. Joseph Peter and co-workers47 have prepared substituted
imidazolinones which inhibited the abnormal cell growth in human body. Stefama Lauter
and co-workers48 have isolated imidazoline from different methods and tested for the
treatment of cytokine release. Imidazoline derivatives have been prepared by Declera
Erickl and co-workers49 showing anti-HIV activity. Ding Ming Wu et al.50 have
prepared novel imidazolines and reported their antifungal activity. C. Alister and
co-workers51 have documented  herbicidal activity of imidazolinone derivatives. Aleksey
N. Vasiliev et al.52 have synthesized imidazolinone derivatives (VI) and reported their
herbicidal activity.
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R1=H              (VI)
R=C2H5
Christopher Preston and co-workers53 have reported the modification of
proline 197 to threonine resulted in an enzyme that was highly resistant (>200-fold) to
inhibition by sulfonylurea herbicides and moderately resistant to triazolopyrimidine and
imidazolinone herbicides. Vedu Akyoshi et al.54 have prepared some new imidazolinone
derivatives (VII) and reported their herbicidal activity. Agrochemical activity of
imidazolinones have been reported by Bascou and co-workers.55






















R3          (VIII)
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Kolhe Vishnu et al.57 have reported anti-AIDS, antibacterial and fungicidal activity
of 5-oxo-imidazolines. B. R. Shah and co-workers58 have prepared some new
imidazolines and reported anticancer and anti HIV activity.
With a view to getting better therapeutic agent, it was contemplated to synthesize
imidazolinones to enhance the overall activity of resulting compounds which have been
described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF (5Z)-5-
   {[2-(4-CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]
   METHYLENE}-3-ARYL-2-PHENYL-3,5-DIHYDRO-4H-
    IMIDAZOL-4-ONES
Studies on Chemical Entities....
                      Imidazolinones...
159
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF ( 5Z ) - 5 - { [ 2 - ( 4 -
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-3-ARYL-
2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES
5-Oxo-imidazolines play a vital role owing to their wide range of biological
activities. Looking to the interesting properties of imidazolinones, it  was
considered worthwhile to synthesize a series of 5-oxo imidazolinones of Type
(IX) for obtaining biologically potent agents which were prepared by reacting
(4Z)-4-{[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methylene}-2-phenyl-1,3-
oxazol-5(4H)-one (azalactone) with different aromatic amines in dry pyridine. The
azalactone were prepared by well known Erlenmeyer azalactone synthesis, as shown in
below.
The constitution of the synthesized products have been characterized by using
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
biological activities of synthesized compounds were compared with standard drugs.
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Alkane   C-H str. (asym.) 2968 2975-2950 59
-CH3   C-H str. (sym.) 2852 2880-2860  ,,
  C-H i.p.def. (asym.) 1474 1470-1435  ,,
Aromatic   C-H  str. 3054 3090-3030 60
  C=C str. 1511 1540-1480  ,,
  C-H o.o.p. (def) 818 835-810  ,,
Imidazo[1,2-a]   C=N str. 1599 1600-1650  ,,
pyridine   C-N str. 1146 1220-1020  ,,
Imidazole   C=O str. 1651 1760-1655 59
ring   C=N str. 1599 1650-1580  ,,
  C=C str. 1489 1540-1480  ,,
Halide   C-Cl str. 749 800-600 60
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range :
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    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF (5Z)-5-{[2-(4-CHLOROPHENYL) IMIDAZO[1,2-
a]PYRIDIN-3-YL]METHYLENE}-3-(4-METHYLPHENYL)-2-PHENYL-3,5-
DIHYDRO-4H-IMIDAZOL-4-ONE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
       1 2.27   3H singlet Ar-CH3             -
       2 6.58-6.62   2H doublet Ar-H(j,j’)        J=12.1
       3 6.89-6.93   2H doublet Ar-H(k,k’)        J=12.4
       4 7.03-7.24   4H multiplet Ar-H (l,m,n,o) -
       5 7.33-7.66   5H multiplet           Ar-H (d,e,f,g,h) -
       6 7.73-7.77           2H doublet Ar-H (c,c’)        J=11.2
       7 7.90-7.94   2H doublet Ar-H(b,b’)        J=12.6
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF ( 5Z ) - 5 - { [ 2 - ( 4 -
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-3-ARYL-
2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES
[A] Synthesis of 2-(4-Chlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde
See Part-I [A], Section-I [B].
[B] Synthesis of  (4Z)-4-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-2-phenyl-1,3-oxazol-5(4H)-one
To a solution of  2-(4-chlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde (2.28
gm, 0.01 mol), acetic anhydride (7.6 ml, 0.075 mol), hippuric acid (4.4gm, 0.025 mol)
and sodium acetate (2.46 gm 0.03 mol) was added and heated on a waterbath for  4-5
hr. The resulting solution was poured on to crushed ice, thus the solid seperated was
isolated and crystallized from dioxane. Yield 59%, m.p. 176oC.
[C] Synthesis of (5Z)-5-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]
methylene}-3-(4-methylphenyl)-2-phenyl-3,5-dihydro-4H-imidazol-4-one
A solution of  (4Z)-4-{[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]
methylene}-2-phenyl-1,3-oxazol-5(4H)-one (3.99 gm, 0.01 mol) and p-toluidine
(1.27gm, 0.01 mol) in dry pyridine (25 ml) was refluxed for 12 hr. on oil bath. The
content was poured on to crushed ice and neutralized with HCl, the isolated product
crystallized from dioxane. Yield 63%, m.p. 134oC; Anal. Calcd. for C30H21ClN4O;
Requires : C, 73.69; H, 4.33; N, 11.46 %; Found : C, 73.68, H, 4.32, N, 11.45 %.
Similarly other (5Z)-5-{[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-3-aryl-2-phenyl-3,5-dihydro-4H-imidazol-4-ones were prepared. The
physical constants are recorded in Table No. 9.
[D] Biological evaluation of (5Z)-5-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin
-3-yl]methylene}-3-aryl-2-phenyl-3,5-dihydro-4H-imidazol-4-ones.
Antimicrobial activity was carried out as described in Part-I [A], Section-I [D]. The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 9.
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 Heterocycles with fluorine atom are generally metabolically stable and fluorine
is considered as a bioisostere of a hydrogen atom, many pharmaceutical products
contain fluorine atom. Fluconazole with fluorine atom used as antifungal agent. Organic
compounds with fluorine atoms having significant dipole moment because fluorine is highly
electronegative atom. Synthetic difluorobenzene derivatives exhibit pronounced
pharmacological activities. Difluorobenzene derivatives have been found to be potent in
intermediate in medicinal, agriculture and industrial chemistry.
THERAPEUTIC IMPORTANCE
Difluorobenzene derivatives are associated with broad spectrum of  biological activities.
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It is revealed from the literature survey that difluorobenzene derivatives have









Michael Gutschow et al.13 have synthesized pthalimido-2,4-difluorobenzenes (I) as
analogues of thalidomide and used as inhibitor of tumor necrosisfactor-α production (TNF-α).
Horoshi Miqauchi and co-workers14 have synthesized triazoles (II) with
difluorobenzene in eight steps from m-difluorobenzene. The synthesized compound shows
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Wei Yan Sun et al.15 have synthesized cyclo saligenyl pronucleotides of 5-iodo
and 5-trifluoromethyl-1-(2-deoxy-β−D-ribofuranoxyl)-2,4-difluorobenzene mimics of
thymidine and investigated them as a potential anticancer agents. Baker N. R. and
co-workers16 have synthesized 1-(2,3-epoxypropoxy)-2(4)-fluorobenzenes and their
corresponding 1-(2-hydroxy-3-morpholinopropoxy and piperazino)-fluorobenzene
derivatives and evaluate them as inotropic and cronotropic active agents. The
synthesized compounds act as potential phosphodiesterase (PDE) inhibitors with
desirable biological activities.
Salomon Stavchansky and co-workers17 have synthesized newer fluorinated
cafficacid phenyl ester (CAPE) (III) and evaluated their cytotoxic and cytoprotective
effects against menadione-induced cytotoxicity in human umbilical vein endothelial cells.
Philip A. Curpino et al.18  have synthesized fluorinated analogues (IV) of
capromorelin to identify long acting growth hormone secretagogue (GHSs) that
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A group of unnatural 1-(2-deoxy-β−D-ribofuranosyl)-2,4-difluorobenzenes
designed as thymidine mimics and evaluated as antiviral and anticancer agents19. These
group of compounds evaluated for variety of antiviral assay system [Herpes Simplex
virus (HSV-1, HSV-2), Varicella-Zoster virus (VZV), Vaccinia virus, Vesicular
Stomatitis, Cytomegalo  virus (CMV) and Human Immunodeficiency virus (HIV-1,
HIV-2)] and also tested for antiviral and anticancer activity.
Krishna C.  Joshi  and co-workers 20 have synthesized 3,6-diaryl-7-
arylazoimidazo[1,2-b][1,2,4]triazines by the cyclocondensation of 3-amino-5-
aryltriazines and α
−
oxo-N-aryl-α-arylethanehydrazonoylbromides and screened for
various biological activities. G. Gaillerm et al.21 have synthesized 5’-deoxy-5’-[(difluoro-
methyl)thio]adenosine and investigated for their inhibitory activities towards
5’-methylthioadenosine (MTA) nucleosidase from Escherichia coli.
T. G. Muralidhar et al.22 have synthesized dihydropyrimidine-one analogues,
among this (V) and (VI) give excellent selectivity (>880-fold) over several other
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The universal template approach to drug design forsees that difluorobenzene can
be modified in such a way to achive better therapeutic agents, we have synthesized
chalones, cyanopyrans, pyrimidines, cyanopyridones  bearing difluorobenzene nucleus.
These study is described in the following parts.
PART-I    : STUDIES ON CYANOPYRANS
PART-II  : STUDIES ON  PYRIMIDINES
PART-III : STUDIES ON  CYANOPYRIDONES
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 INTRODUCTION
The chemistry of pyran with different functional group exhibit wide range of
applications in the field of medicinal science, dyes, insecticides and sweet smelling
substances. Pyran ring system is also present in nature abundantly such as in large number
of natural coloured compounds in Vitamin E, hemorrhagic compound in cloves,  in certain
alkaloids and in other substances.
Pyran is a doubly unsaturated six membered ring system with a single oxygen as
hetero atom. The two double bonds may be conjugated as α, β or 1,2-pyran or isolated
as in α,δ or 1,4-pyran.
A degree of stabilisation of the pyran nucleus is achieved by substituting phenyl
group in the 2 or 4 and preferably also in the 6 position.
SYNTHETIC ASPECT
Various methods for the preparation of pyran derivatives have been cited
in the literature.1-10
1. Reaction between α,β-unsaturated carbonyl system with  (CH2CN)2 led to
corresponding 2-amino-3-cyano-4H-pyrans.11
2. Some alkylidene 2H-pyrans were synthesized12 by thermal electrolyting ring
closure of divinyl alkenyl.
3. Svete J. et al.13 have synthesized fused 3-amino-2H-pyran-2-ones by solid
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5. Abdel Ghany H. et al.15 have prepared new pyran derivatives by condentation
of  2-coumarylidene malononitriles with active methylene containing compound.
MECHANISM
The reaction of malononitrile with α,β-unsaturated system leads to the formation
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THERAPEUTIC IMPORTANCE














13. Inhibitors of cell proliferation32
14. Gastric acid secretion inhibitor33
Some of the pyran derivatives (I) have been patented for their use as
antihypertensive34, antiestogens35, antagonist36,37, antitumor38 and antiviral39 activities.
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Synthesis and anticancer activity of pyran (II) containing flourine have been
reported by Mohamed et al.41 4H-pyran (III) were prepared to enhance the anticancer
and anti HIV activity.
El-Subbagh and co-workers42 have synthesized cyanopyran derivatives and
showed their antiviral activity. Corbou Romuld et al.43 have reported cyanopyran
derivatives (IV) which have significant pharmacological activity.
Zwaagstra Mariel44 have synthesized newer pyran derivatives show antiashamatic
activity. Boyer Frederick et al.45 have prepared some new 2-amino-3-cyano-4H-pyran
and reported for anti HIV agent and antiviral activity. Sharanin Y. U. A. et al.46 have
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Moreover, Fathy F. Abdel-Latif et al.47 have reported the synthesis of 2-amino-
3-cyanopyran derivatives and studied their biological activity. Piao Minz Zhu et. al.48
have prepared biologically active 2-amino pyran derivatives.
Recently, Hanafusa T. et al.49 have reported some new cyanopyran as functional
promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific
methylation. Williamson H. S. et al.50 have described pyran as a truncated  protein from
enteropathogenic Escherichia coli acts as an antagonist. Yeo H. and Li Y. et al.51 have
described the synthesis and antiviral activity of helioxanthin analogues. David-Cordonnier
M. H. et al.52 have synthesized pyrano compounds as antitumor agents.
Iwahashi Y. and co-workers53 have synthesized  4-hydroxy-4H-furo[3,2c]pyran-
2(6H)-one, is one of the best characterized and most widely disseminated mycotoxins
found in agriculrueal products.  Y. Osada et al.54 investigated antioxidative activity of
2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one.
Morever, Asche C. et al.55 have reported some novel cyanopyran for antitumour
activity and structure-activity relationships of 5H-benzo[b]carbazoles. Moon C. H.
et al.56 have found some novel benzopyran analog, attenuates hypoxia-induced cell death
via mitochondrial KATP channel and protein kinase C-epsilon in heart-derived H9c2
cells. Howe A.Y. et al.57  have described some novel nonnucleoside inhibitor of hepatitis
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Thus, diverse biological activities have been encountered in compounds containing
cynopyran ring system. Therefore it was considered wothwhile to synthesized cyanopyran
derivatives containing difluorobenzene nucleus which have been descried as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF (2E)-1-(2,4-
  DIFLUOROPHENYL)-3-ARYLPROP-2-EN-1-ONES
SECTION-II :SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-
  6-(2,4-DIFLUOROPHENYL)-4-ARYL-4H-PYRAN-3-CARBONITRILES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF (2E)-1-(2,4-DIFLUORO
PHENYL)-3-ARYLPROP-2-EN-1-ONES
Chalcone derivatives occupy a unique place in the field of medicinal chemistry
due to wide range of biological activities exhibited by them, prompted by this fact, the
preparation of chalcones of Type (X) have been carried out by condensation of 2,4-
difluoroacetophenone with various aromatic aldehydes.
The constitution of the synthesized products have been characterized by using
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesized compounds were compared with standard drugs.
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Reaction Scheme
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 Observed
Aromatic C-H  str. 3017 3090-3030 60
C=C str. 1545 1540-1480  ,,
C-H i.p. (def.) 1094 1125-1090  ,,
C-H o.o.p. (def) 1031 1070-1000  ,,
α,β-unsaturated C=O str. 1678 1700-1640 59
ketone C=C str. 1573 1644-1618  ,,
C-O str. 1047 1210-1000  ,,
Vinyl CH=CH str. 3033 3050-3000  ,,
Halogen C-Cl str. 713 800-600  ,,
C-F str. 1237 1400-1000  ,,
Type        Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF (2E) -1-(2,4-DIFLUOROPHENYL)-3-(4-
CHLOROPHENYL )PROP-2-EN-1-ONE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range :
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1 2.52 3H singlet Ar-CH3     -
2 6.883-6.908 1H dd Ar-H(f)             J=7.5, J=0.9
3 7.24-7.27 1H doublet Ar-H(e) J=9.5
4 7.29-7.32 1H doublet -CH(c) J=9.6
5 7.64-7.67 2H doublet Ar-H(a,a’) J=9.2
6 7.87-7.91 1H doublet -CH(d) J=12.4
7 8.0306 1H doublet Ar-H(g)     -




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF (2E)-1-(2,4-DIFLUOROPHENYL)-3-(4-
METHYLPHENYL)PROP-2-EN-1-ONE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF (2E)-1-(2,4-DIFLUORO
PHENYL)-3-ARYLPROP-2-EN-1-ONES
[A] Synthesis of  2,4-Difluoroacetophenone
The 1,3-difluorobenzene (11.4gm, 0.1 mol) in 50 ml dichloromethane was cooled
at 00C. To this add anhydrous AlCl3 (18.66gm, 0.15 mol) and acetyl chloride (9.36gm,
0.12 mol) at 00C with constant stirring. The resulting mixture was further stirred at
5-100C for 8 hour. After cooling, the dichloromethane layer poured on to crushed ice
containing diluted HCl. The separated dichloromethane layer, wash  with water, distilled
out dichloromethane and product was isolated. Yield 56%, b.p192oC, Anal. Calcd. for
C8H6F2O : Require: C, 61.54, H, 3.87, N, 0.0 % ; Found: C, 61.06, H, 3.86,  N, 0.0
%.
[B] Synthesis of  (2E)-1-(2,4-Difluorophenyl)-3-(4-methoxyphenyl)prop-2-en-
1-one
To  a  s o l u t i o n  o f  2 , 4 - d i f l u o r o a c e t o p h e n o n e ( 1 . 5 6 g m ,  0 . 0 1  m o l ) ,
4 - methoxybenzaldehyde (1.36gm, 0.01 mol) in ethanol (25 ml) and 40% NaOH solution
was added till the solution become basic. The reaction mixture was stirred for 24 hr. at
room temperature. The content was poured on to crushed ice. Upon neutralization the
solid was isolated and product was crystallized from ethanol. Yield 62%; m.p.94oC.
Anal. Calcd. for C16H12F2O2; Required : C,70.07; H, 4.41 ; N, 0.0% ; Found : C, 69.45;
H, 4.40; N, 0.0%.
Similarly, other (2E)-1-(2,4-difluorophenyl)-3-arylprop-2-en-1-ones were
prepared. The physical data are recorded in Table No.10
[C] Biological evaluation of (2E)-1-(2,4-Difluorophenyl)-3-arylprop-2-en-
1-ones
Antimicrobial testing were carried out as described in Part-I [A] Section-I [D].
The zones of inhibition of test solutions are recorded in Graphical Chart No.10
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SECTION - II
S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F  2 - A M I N O - 6 -
(2,4-DIFLUOROPHENYL)-4-ARYL-4H-PYRAN-3-CARBONITRILES
Cyanopyran derivatives have been found to be associated with various
pharmacological activities. These findings encouraged us to synthesized, some new
2 - a m i n o - 6 - (2,4-difluorophenyl)-4-aryl-4H-pyran-3-carbonitrile derivatives of
Type (XI) by the cyclocondensation of (2E)-1-(2,4-difluorophenyl)-3-arylprop-2-en-
1-ones of Type (X) with malononitrile in pyridine.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed  Reported
Alkane C-H str. (asym.) 2949 2975-2950 59
-CH3 C-H str. (sym.) 2875 2880-2860  ,,
C-H def. (asym.) 1449 1470-1435  ,,
C-H def. (sym.) 1365 1390-1370  ,,
Aromatic C-H  str. 3057 3090-3030 60
C=C str. 1505 1540-1480  ,,
C-H i.p. def. 1106 1125-1090  ,,
C-H o.o.p. def. 809 835-810  ,,
Pyran C=C str. 1622 1650-1520  ,,
Nitrile C=N str. 2220 2240-2120 59
Amine N-H str. 3338 3410-3380  ,,
Ether C-O-C str. 1244 1260-1200  ,,
Halide C-F str. 1024 1400-1000  ,,
IR SPECTRAL STUDIES OF 2-AMINO-6-(2,4-DIFLUOROPHENYL)-4-(4-
METHOXYPHENYL)-4H-PYRAN-3-CARBONITRILE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
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   Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER




    (δppm)
 Relative No.
  of protons
Multiplicity Inference
1 3.94 3H singlet Ar-OCH3    -
2 5.29 1H singlet Ar-H(g)    -
3 6.904-6.929 2H doublet Ar-H(a,a’) J=7.8
4 7.03-7.06 1H doublet Ar-H(d) J=9.4
5 7.118-7.149 2H doublet Ar-H(b,b’)        J=9.8
6 7.61 1H singlet Ar-H(c)                -
7 7.80 1H singlet Ar-NH2               -
8 8.21-8.23 1H dd Ar-H(e) J=6.8
9 8.311 1H doublet  Ar-H(f)     -
NMR SPECTRAL STUDIES OF 2-AMINO-6-(2,4-DIFLUOROPHENYL)-4-(4-
METHOXYPHENYL)-4H-PYRAN-3-CARBONITRILE
  J Value
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-6-(2 ,4-
DIFLUOROPHENYL)-4-ARYL-4H-PYRAN-3-CARBONITRILES
[A] Synthesis of (2E)-1-(2,4-Difluorophenyl)-3-arylprop-2-en-1-ones
See Part-I [B], Section-I [B].
[B] Synthesis of 2-Amino-6-(2,4-difluorophenyl)-4-(4-methoxyphenyl)-4H-
pyran-3-carbonitrile
A mixture of (2E)-1-(2,4-Difluorophenyl)-3-(4-methoxyphenyl)-prop-2-en-1-
one (2.74 gm, 0.01 mol) and malononitrile (0.66gm, 0.01 mol)  in pyridine (20 ml), was
heated under reflux for 10 hr. on oilbath. The reaction mixture was cooled and poured
on to crushed ice. The residue was  neutralized with 20% HCl, where upon a solid
separated out, which was filtered and crystallized from ethanol. Yield 58%, m.p.160oC
Anal. Calcd.for C19H14F2N2O2; Requires: C,67.05; H, 4.15; N, 8.23 %; Found: C, 66.99;
H, 4.14; N, 8.22 %.
Similarly, other 2-amino-6-(2,4-difluorophenyl)-4-aryl-4H-pyran-3-carbonitriles
were prepared. The physical data are recorded in Table No.11
[C] Biological evaluation of 2-Amino-6-(2,4-difluorophenyl)-4-aryl-4H-pyran-
3-carbonitriles
Antimicrobial testing were carried out as described in Part-I [A], Section-I [D].
The zones of inhibition or test solution are recorded in Graphical Chart No.11
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 INTRODUCTION
Pyrimidine is the most important member of all the diazines as this ring  system
occurs widely in living organisms. The naturally occuring pyrimidine derivatives was first
isolated by Garbial and Colman in 1870, and its structure was confirmed in 1953 as 5-β-
D-gluco-pyranoside of divicine. Pyrimidine derivatives which occurs in natural products1
like nucleic acid, vitamin-B and having remarkable pharmaceutical importance because of
their broad spectrum of  biological activities. Several analogs of nucleic acids like fluorouracil
which has been used in cancer treatment. Pyrimidines are among those molecules that
make life possible as being some of the building blocks of DNA and RNA.
Some pyrimidines of physiologically as well as pharmacologically importance are








Pyrimidine is considered to be a resonance hybrid of the charged and uncharged
cannonical structures, its resonance energy has been found to be less than benzene or
pyridine.
SYNTHETIC ASPECT
A very important general method for preparing pyrimidines is the condensation
between a three carbon compounds of the type YCH2Z, where Y and Z = COR, CO2R,
CN, and compounds having the amidine structure R(C=NH)NH2, where R = R
(an amidine),  SH or SR (thiourea or its s-derivative), NH2 (guanidine); the condensation
is carried out in the presence of sodium hydroxide or sodium ethoxide. This general
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Pyrimidines can also be prepared by cycloaddition reaction of 1,3,5-
triazines,which act as electron deficient dienes.
The reaction of chalcone with guanidine hydrochloride in presence of  potassium
t-butoxide in t-butanol yielded corresponding 2-amino pyrimidine   derivatives.2  Pratibha
Sharma and co-workers3 have investigated the  insertion of dimethylvinylidene carbene
into azo moiety was investigated in order to synthesize 4,6-dimethyl-5-[2-(2-methylprop-
1-enyl)-1H-benzimidazol-1-yl]pyrimidine-2(5H)-thiones under kinetically controlled
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Rasaki4 synthesized 2-amino-pyrimidine by the reaction of chalcone epoxides
with guanidine carbonate in xylene. Sham M. Sondhi et al.5 have synthesized pyrimidine
derivatives by an efficient, one-pot reaction of functionalized amines with either
4-isothiocyanato-4-methyl-2-pentanone or 3-isothiocyanatobutanal.
There are many other methods of pyrimidine ring synthesis which are of more limited
scope. The reaction of 1,3-dicarbonyl compound or an equivalent  reagent with formamide































































Studies on Chemical Entities....
                            Pyrimidines...
205
THERAPEUTIC IMPORTANCE
Large number of drugs possess pyrimidine ring system. Well-known antimalarial
agents like hypotensive agent like minoxidil (III), pyrimethamine (V),  antibacterial agent
like ormetraprim (V) possess pyrimidine ring system.
Pyrimidine derivatives exhibit a wide spectrum of pharmacological activities











Marie Gompel and co-workers16 have showed that meridianins inhibit various
protein kinases such as cyclin-dependent kinases, glycogen synthase kinase-3, cyclic
nucleotide-dependent kinases and casein kinase (VI). Alistair H. et al.17 have


















          (III)           (IV)           (V)
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in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative
potency and selectivity of these compounds has been rationalized using QSAR and
structure based modelling (VII).
S. S. Sangapure18 have tested the antimicrobial activity of benzofuro[3,2-
d]pyrimidine derivatives (VIII). El Sayed19 have synthesized alkylated substituted
mercapto pyrimidine derivatives (IX) and studied their anticancer and antineoplastic
activity. H. Y. Moustafa20 have  reported some pyrimidine derivatives and studied their
biological activities.
Patil L. R. et al.21 have synthesized some new pyrimidines bearing paracetamol
and imidazolyl moieties. B. J. Ghiya et al.22 synthesized some mercapto pyrimidine
derivatives (X) and screened for their anticancer, antitubercular and anti HIV activities.
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Michael D. Varney24 have synthesized and evaluated biological activity of 5-thia-
2,6-diamino-4(3H)-oxopyrimidines (XII) as potent inhibitors of Glycinamide
Ribonucleotide Transformylase with potent cell growth inhibition.
Viney Lather and co-workers25 have been proposed to predict the anti-HIV
activity of dihydro(alkylthio)(naphthylmethyl)oxopyrimidines. These models are capable
of providing lead structures for development of potent but safe anti-HIV agents  (XIII).
Mai  A. et al.26 have synthesized 5-alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-
3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-
nucleoside reverse transcriptase inhibitors belonging to the DABO family. Yamamoto I.
et al.27 have reported some oxopyrimidines searching for the novel antagonist or agonist
of  barbiturates to the sleep mechanism based on the uridine receptor. Huang Y. L.
et al.28 have synthesized non-classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-
triaminopyrimidines and 2,4-diamino-6(5H)-oxopyrimidines as antitumor activity.
Shimizu T. et al.29 have described N3-substituted uridine and related pyrimidine
nucleosides as antinociceptive effects in mice. Sanmartin C. et al.30 have prepared new
symmetrical derivatives as cytotoxic agents and apoptosis inducers. Agarwal A. et al.31







     (XIII)
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   (XIV)
agents. Shigeta S. et al32 have been synthesized 5-alkyl-2-thiopyrimidine nucleoside
analogues and examined for antiviral activities against Herps Simplex virus (HSV),
Varicella-Zoster virus (SZV) and Human Cytomegalo virus (HCMV).
H. S. Joshi et al.33 have sythesized some new pyrimidines (XIV) and reported as
antitubercular and antimicrobial agents.
Looking to the diversified activities exhibited and in continuation of our work on
the synthesis of biologically active heterocycles, the synthesis and biological screening
of pyrimidine derivatives have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-
  DIFLUOROPHENYL)-6-ARYLPYRIMIDIN-2-AMINES
SECTION-II :SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-
  DIFLUOROPHENYL)-6-ARYLPYRIMIDINE-2(1H)-THIONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-DIFLUORO
PHENYL)-6-ARYLPYRIMIDIN-2-AMINES
Aminopyrimidines represent one of the most active classes of compounds
possessing a wide spectrum of biological activities, such as significant in vitro activity
against DNA and RNA viruses including polio viruses, diuretic, antitubercular spermidical
etc. These valid observation led us to synthesize 4-(2,4-difluorophenyl)-6-arylpyrimidin-
2-amines of Type (XII) by cyclocondensation of (2E)-1-(2,4-difluorophenyl)-3-arylprop-
2-en-1-ones of Type (X) and guanidine hydrochloride in presence of KOH as catalyst.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2958 2975-2950 34
-CH3 C-H str. (sym.) 2867 2880-2860  ,,
Aromatic C-H  str. 3079 3090-3030 35
C=C str. 1508 1540-1480  ,,
C-H i.p. def. 1087 1125-1090  ,,
C-H o.o.p. def. 811 835-810  ,,
Pyrimidine C=N str. 1543 1580-1520 34
C-N str. 1187 1220-1020  ,,
Amine N-H str. 3398 3410-3380  ,,
Ether C-O-C str. 1245 1260-1200 35
Halide C-F str. 1364 1400-1000  ,,
IR SPECTRAL STUDIES OF 4-(2,4-DIFLUOROPHENYL)-6-(4-METHYL
PHENYL)PYRIMIDIN-2-AMINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 3.87 3H singlet Ar-OCH3     -
2 4.16 1H singlet Ar-H(c)     -
3 6.91-6.94 2H doublet Ar-H(a,a’) J=9.8
4 6.94-6.96 1H doublet Ar-H(f) J=6.2
5 7.328-7.348 2H doublet Ar-H(b,b’) J=7.2
6 7.55 2H singlet Ar-NH2     -
7 7.573-7.577 1H doublet Ar-H(d) J=1.2




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 4-(2,4-DIFLUOROPHENYL)-6-(4-METHOXY
PHENYL)PYRIMIDIN-2-AMINE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-DIFLUORO
PHENYL)-6-ARYLPYRIMIDIN-2-AMINES
[A] Synthesis of (2E)-1-(2,4-Difluorophenyl)-3-arylprop-2-en-1-ones
See Part-I [B], Section-I [B] .
[B] Synthesis of 4-(2,4-Difluorophenyl)-6-(4-methoxyphenyl)pyrimidin-2-
amine
A mixture of (2E)-1-(2,4-difluorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
(2.74 gm, 0.01 mol) and guanidine hydrochloride (1.10gm, 0.01 mol) in methanol
(20 ml) was refluxed on waterbath  in presence of alcoholic KOH for 8 hr. The excess
solvent was distilled off and the residue was neutralized with 20 % HCl, the separated
solid was filtered out and crystallized from ethanol. Yield 57 %, m.p. 178oC Anal. Calcd.
for C17H13F2N3O Requires: C, 65.17; H, 4.18; N, 13.41 % Found: C, 65.15; H, 4.16,
N, 13.40 %.
Similarly, other 4-(2,4-difluorophenyl)-6-arylpyrimidin-2-amines  were prepared.
The physical data are recorded in Table No. 12.
[C] Biological evaluation of 4-(2,4-Difluorophenyl)-6-arylpyrimidin-2-amines
Antimicrobial testing were carried out as described in Part-I [A], Section-I [D].
The zones of inhibition of test solution are reported in Graphical Chart No. 12.
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-DIFLUORO
PHENYL)-6-ARYLPYRIMIDINE-2(1H)-THIONES
Compounds containing pyrimidine ring are widely available in nature. Many thio
pyrimidine derivatives are reported to possess different therapeutic activities. In view of
these findings, it was considered worthwhile to synthesize some new 4-(2,4-
difluorophenyl)-6-arylpyrimidine-2(1H)-thiones of  Type (XIII) to study their therapeuric
activities. Thio pyrimidine derivatives of  Type (XIII) have been prepared by the reaction
of the chalcones of Type (X) with thiourea in presence of basic catalyst  in ethanol
shown as under.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infra red and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2937 2975-2950 34
-CH3 C-H str. (sym.) 2833 2880-2860  ,,
Aromatic C-H  str. 3047 3090-3030 35
C=C str. 1497 1620-1430  ,,
C-H i.p. def. 1048 1070-1000  ,,
C-H o.o.p. def. 811 835-810  ,,
Thio pyrimidine C=S str. 1582 1590-1550 34
Amine N-H str. 3219 3554-3350  ,,
Vinyl CH=CH str. 3021 3050-3000  ,,
Ether C-O-C str. 1213 1260-1200  ,,
Halide C-F str. 745 800-600 35
IR SPECTRAL STUDIES OF 4-(2,4-DIFLUOROPHENYL)-6-(4-METHOXY
PHENYL)PYRIMIDINE-2(1H)-THIONE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 3.78 3H singlet Ar-OCH3     -
2 5.60 1H singlet Ar-H(c)     -
3 6.66-6.69 2H doublet Ar-H(b,b’) J=9.8
4 6.81-6.83 1H doublet Ar-H(f) J=7.8
5 6.93-6.96 2H doublet Ar-H(a,a’) J=10.3
6 7.31-7.35 1H dd Ar-H(e)         J=12.1, J=1.3




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-DIFLUORO
PHENYL)-6-ARYLPYRIMIDINE-2(1H)-THIONES
[A] Synthesis of (2E)-1-(2,4-Difluorophenyl)-3-arylprop-2-en-1-ones
See Part-I [B], Section-I [B].
[B] Synthesis of 4-(2,4-Difluorophenyl)-6-(4-chlorophenyl)pyrimidine-2(1H)-
thione
A mixture of  (2E)-1-(2,4-difluorophenyl)-3-(4-chlorophenyl)prop-2-en-1-one
(2.78 gm, 0.01 mole) and thiourea (0.78gm, 0.01 mol) in ethanol (15 ml) was refluxed
on a waterbath in presence of alcoholic KOH for 12 hr. The solvent was distilled off and
the residue was neutralized with dilute HCl, the separated solid was filtered out and
crystallized from ethanol. Yield 59 %, m.p. 160oC Anal. Calcd. for C16H9ClF2N2S
Requires: C, 57.40; H, 2.71; N, 8.37 % Found: C, 57.38; H,2.70, N, 8.36%.
Similarly, other  4-(2,4-difluorophenyl)-6-arylpyrimidine-2(1H)-thiones were
prepared. The physical data are recorded in Table No. 13.
[C] Biological evaluation of  4-(2,4-Difluorophenyl)-6-arylpyrimidine-2(1H)-
thiones
Antimicrobial testing were carried out as described in Part-I [A], Section-I [D].
The zones of inhibition of test solution are reported in Graphical Chart No. 13.
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INTRODUCTION
Pyridones, which belongs to an important group of heterocyclic compounds have
been extensively explored for their applications in the field of medicinal chemistry.
Pyridones, with a carbonyl group at position 2 (I) have been subject of extensive study
in recent past. Numerous reports have appeared in the literature, which highlight their
chemistry and use.
Pyridones are derivatives of pyrimidines with carbonyl group at 2-position (I).
Some 2-pyridones are physiologically as well as pharmacologically important which are
as under, eg. Ciclopirox (II), Methylprylon (III) and Amrinone (IV).
SYNTHETIC ASPECT
1. G. Simchen and G. Entemman1 have synthesized 2-pyridone in which the ring
nitrogen comes from a nitrile group in acyclic precursor.
2. M. A. Sluyter and co-workers2 have prepared fused 2-pyridones
3.     K. Folkers and S. A. Harris3 have synthesized 3-cyano-2-pyridone (V) by
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Morishita Koji et al.14 have synthesized m-(2-oxo-l,2-dihydropyridyl)urea
derivatives (VI) possessing cholesterol acyltransterase (ACAT) inhibitory activity and
are useful for the treatment of hyperlipidemia and arteriosclerosis.
Moreover, 2-pyridones documented as S3 site of thrombin inhibitor15, herbicidal16,
SH2 domain inhibitor












Studies on Chemical Entities....
                      Cyanopyridones...
227
Collins et al.21 have prepared heteroaryl pyridones (VII) as GABA α,β ligands.
Pednekar22 have synthesized fused 2-pyridone derivatives (VIII), (IX) and (X) as useful
heterocyclic moieties as they possess broad spectrum of biological activities such as
antiviral, CNS depressant, bactericidal and ulcer inhibitor.
M. G. Nizamuddin et al.23 have prepared cyanopyridone derivatives (XI) and
documented their antifungal activity. Tanaka Akira et al.24 have prepared pyrazolo
pyridone derivatives (XII).
Peter and co-workers25 have described pyridinylmethyl substituted pyridines and
pyridones as angiotensin II antagonist. H. Posnes26 have synthesized 2-pyridones and
2-pyrones as physiologically active compounds. Mukhtar Hussain Khan and
co-workers27,28 have prepared 2-pyridone derivatives (XIII) and (XIV) which possess
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Upadhyay et al.29 have documented cyanopyridone derivatives, which showed
antifungal and antileishmanial activities. E. Amer30 prepared 3-cyano-2-pyridone
derivatives (XV) displaying high antimicrobial activity. Abou El-Fotooh and





















        (XV)        (XVI)
Adnan A. Bekhit and Azza M. Baraka32 have synthesized 4-aryl-6-(4-pyridyl)-
2-oxo-1,2-dihydropyridine-3-carbonitriles for cardiotonic activity and their in vivo
cardiovascular effects. In addition these compounds proved to be non-toxic and well
tolerated by mice up to 250 mg/kg orally and upto 125 mg/kg through parenteral route.
Abdel-Gali l  E.  Amr and Mohamed M. Abdulla33 have invest igated
anti-inflammatory profile of synthesized heterocyclic pyridones fused with sterodial
structure (XVII). Initially the acute toxicity of the compounds was assayed via the
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Herbarth O. and co-workers34 investigated excretion patterns of nucleosides of
68 cancer patients with malignant and benign tumours and 41 healthy controls have been
studied. Significant elevations in the total sum and the concentrations of indicator
nucleosides 2-pyridone-5-carboxamide-N1-ribofuranoside indicate tumour with a
sensitivity of 54% and specificity of 86%. The comparison with carcinoembryonic
antigen, cancer antigen and tissue polypeptide antigen indicates that urinary nucleosides
may be usefull tumour markers.
Thus significant biological properties associated with cynopyridones derivative
have aroused considerable interest to design the compounds with better drug  potentials
and to study their pharmacological profile, the synthesis and therapeutic evaluation of
them, have been described as under.
SECTION I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-
  DIFLUOROPHENYL)-6-ARYL-2-OXO-1,2-DIHYDROPYRIDINE-
            3-CARBONITRILES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-DIFLUOROPHENYL)-
6-ARYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONITRILES
Pyridone derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of pyridone derivatives of Type (XIV)
by the condensation of chalcones of Type (X) with ethylcyanoacetate in presence of
ammonium acetate as shown under.
The constitution of the synthesized products have been characterized by using
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The













Type-(XIV)R = Aryl         Type (X)
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 Observed
Aromatic C-H  str. 3192 3090-3030 35
C=C str. 1492 1540-1480  ,,
C-H o.o.p. (def) 828 835-810  ,,
Pyridone ring C = N str. 2215 2240-2120  ,,
C=O str. 1668 1760-1655  ,,
N-H str. 3346 3450-3250  ,,
N-H def. 1584 1650-1580  ,,
Halide C-Cl str. 799 800-750 36
C-F str. 1149 1400-1000  ,,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 4-( 2 , 4 - D I F L U O R O P H E N Y L ) - 6 - ( 4 -
CHLOROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range :
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1 3.87 3H singlet Ar-OCH3     -
2 7.41-7.45 2H doublet Ar-H(b,b’) J=12.1
3 7.52-7.54 1H doublet Ar-H(f) J=6.8
4 7.75 1H singlet Ar-H(c)     -
5 7.86-7.90 1H dd Ar-H(e)              J=6.8, J=1.3
6 8.04-8.07 2H doublet Ar-H(a,a’) J=9.4
7 8.12-8.13 1H doublet Ar-H(d) J=2.4




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 4-(2,4-DIFLUOROPHENYL)-6-(4-METHOXY
PHENYL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2,4-DIFLUORO
PHENYL)-6-ARYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONITRILES
[A] Synthesis of (2E)-1-(2,4-Difluorophenyl)-3-arylprop-2-en-1-ones
See, Part-I [B], Section-I [B].
[B]    Synthesis of 4-(2,4-Difluorophenyl)-6-(4-methoxyphenyl)-2-oxo-1,2-
dihydropyridine-3-carbonitrile
A mixture of (2E)-1-(2,4-difluorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
(2.74 gm, 0.01 mol), ethyl cyanoacetate (1.13 gm, 0.01 mol) and ammonium acetate
(6.16 gm, 0.08 mol) in absolute alcohol was refluxed for 10 hrs. The reaction mixture
was poured on to crushed ice and seperated product was isolated and crystallized from
ethanol. Yield 66%, m.p. 143°C. Anal. Calcd. for C19H14F2N2O2 ; Required: C, 67.05;
H, 4.15; N, 8.23 %; Found: C, 66.10; H, 4.14; N, 8.22 %.
Similarly other 4-(2,4-Difluoro phenyl)-6-aryl-2-oxo-1,2-dihydropyridine-3-
carbonitriles were prepared. The physical data are recorded in Table No. 14
[C] Antimicrobial activity of 4-(2,4-Difluorophenyl)-6-aryl-2-oxo-1,2-
  dihydropyridine-3-carbonitriles
Antimicrobial testing was carried out as described in Part-I [A], Section-I [D].
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 14
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R       R
NH
N
S
F
F
R
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
3,4-(OCH3)2-C6H3-
4-F-C6H4-
3-Br-C6H4-
3-C6H5-O-C6H4-
4-N(CH3)2-C6H3-
2-OH-C6H4-
2-C4H3O-
C6H5-
4-Cl-C6H4-
2-Cl-C6H4-
4-CH3-C6H4-
4-OCH3-C6H4-
3,4-(OCH3)2-C6H3-
4-F-C6H4-
3-Br-C6H4-
3-C6H5-O-C6H4-
4-N(CH3)2-C6H3-
2-OH-C6H4-
2-C4H3O-
F
F
NH
N
O
R
